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Abstract
Incidence of Clostridium difficile infection, (CDI) in patients receiving antibiotics is
significant. In 2017, there were approximately 223,900 cases of CDI in hospitalized
patients alone (Center for Disease Control [CDC], 2017). Despite enhanced infection
control measures, CDI rates remain prevalent and are associated with increased costs to
healthcare. An integrative literature review and synthesis was performed. Studies were
analyzed to delineate if Lactobacillus containing probiotics, when administered
concurrently with high risk antibiotics, decrease CDI rates for patients in the inpatient
hospital setting. Additional analysis of probiotic safety and a cost versus benefit analysis
was researched. The purpose of the review and analysis was to determine the strength of
evidence for utilization of probiotics. Within this review, the use of probiotics to combat
incidence of CDI was associated with low risk of adverse effects with probiotic use, and
moderate effect on reducing CDI rates. Significant cost savings to inpatient facilities is
also noted. The research findings suggest use of probiotics is associated with improved
patient outcomes by decreasing incidence of CDI, reduced hospital length of stay, and the
prevention of the physical and emotional consequences from CDI. A concept map was
constructed to guide readers through the correlational relationship of a Lactobacillus
probiotic on CDI rates, institutional cost savings, and adverse events. Despite promising
findings in safety, cost reduction, and decreased incidence of CDI, due to high
heterogenicity between studies, details regarding prescribing practices remain unclear.
Therefore, precise recommendations for practice remain unknown and further research is

warranted. These findings provide a foundation of knowledge that may be utilized by the
advanced practice nurse and other healthcare providers. Monitoring for new research that
emerges, or encouragement for further research to be performed, within the hospital
setting, is needed. Until then, the data found within this review provides education related
to the benefits of utilizing probiotics for patients receiving high risk antibiotics with a
subsequent result of decreased incidence of CDI, decreased mortality related to CDI, and
long-term cost savings to an institution. Robust clinical trials are needed to validate the
effectiveness of particular dosages, duration, and species of probiotics. Therefore,
institutional based prescribing guidelines cannot be formed at this time and prescribing
should be left to the judgement of the prescribing provider.
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Section I
Introduction to Inquiry
Introduction
Clostridium difficile infection (CDI) is a gram-positive bacterium that is highly
virulent and is the leading cause of hospital acquired antibiotic associated diarrhea (Lau
& Chamberlain 2016, p. 27). The diagnosis of CDI results in detrimental outcomes as
increased length of hospital stays, increased risk for systemic infection, and increased risk
of morbidity. In addition, CDI results in increased costs to institutions due to costs
accumulated from additional treatment of infection, increased length of hospital stay, and
additional safety measures to prevent the spread of the infection (personal protective
gowns and specialized bleach cleaners), which is often not reimbursed by insurance.
Despite enhanced infection control measures CDI rates remain prevalent in the hospital
setting affecting on average thirteen per one-thousand patients (Center for Disease
Control (CDC), 2017). According to the Cochrane Database, the use of probiotics has
been studied for its effects on CDI rates for many years (Chaturaka, 2018). This leads to
the question of the use of probiotics and can they be efficacious, safe, and cost-effective
method to combatting hospital acquired CDI.
To address the inquiry question, this scholarly inquiry project reviewed current
literature regarding probiotic’s effects on reducing hospital acquired CDI rates.
Background and rationale of the impact of CDI and the biochemical chemical effects of
probiotics are explained. The significance of hospital acquired Clostridium difficile in
terms of mortality rates and cost burdens are highlighted. Purpose and PICOT formed
question is presented to clearly inform the reader, the intent of this scholarly inquiry
paper. Methods and procedures used for content analysis are provided.
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Background and Rationale
CDI is an opportunistic gastrointestinal infection that occurs when normal
intestinal microbiome is disrupted. Symptoms may range from mild diarrhea to severe
colitis. In severe cases, CDI may result in sepsis, ischemic colon, possible colostomy,
and/or death. The criteria of mild to severe CDI along with recommended treatment is
described in Table Al Clinical Definition and Recommended Treatment for Clostridium
difficile Infection in Adults. Use of antibiotics, advanced age, recent hospitalization, and
an immunocompromised state of health are the leading precipitating factors to CDI
(Tilton & Johnson, 2018, p. 280). Risks of developing CDI are further increased for
patients receiving high risk antibiotics such as: Cefepime, Clindamycin, Piperacillin,
Ciprofloxacin, Fluoroquinolones, and Vancomycin, due to the increased disruption of
normal gastrointestinal flora (Tilton & Johnson, 2018, p. 282). Increased incidence of
CDI in hospitals is due to higher presence of the virulent Clostridium difficile strain in
hospital settings (CDC, 2017). Research has shown, up to 20-50 % of hospital surfaces
contain Clostridium difficile spores (McFarland, Ship, Auclair, & Millette, 2018, p. 444).
The high virulence of CDI is due to the Clostridium difficile spores being resistant to
hand sanitizer and many typical disinfectant cleaners, requiring handwashing and
cleaners with bleach to disinfect surfaces (CDC, 2019)
Health care associated CDI is defined as Clostridium difficile infection diagnosed
more than 48 hours after hospital admission and/or less than four weeks after discharge
from a hospital facility (Starn, Harpe, & Cline, 2016, p. 238). CDI has become one of the
top causes of health care associated infections in America. According to the CDC’s
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Antibiotic Resistance Threats report, in 2017 there were approximately 223,900 cases of
CDI (CDC, 2019).
Clostridium difficile infection results in a financial burden of nearly five billion
dollars for American hospitals (CDC, 2017). On average, each incident of hospital
acquired CDI, in the United States, costs between 18,676- 27,408 dollars and this does
not include quality of life adjustments (Heimann, Aguilar, Mellinghof, & Vehreschild,
2018, p. 24). Additional costs accrued are due to increased length of hospital stay,
additional treatment methods (antibiotics, antifungals), need for personal protective
gowns, specialized bleach cleaning products, and additional room cleaning methods
(Zhang et al., 2016). CDI is often coded as a healthcare associated infection resulting in
little to no reimbursement for hospitals that participate in Center for Medicaid Service
programs (CDC, 2017).
Mortality rates associated with CDI are high. According to the CDC (2017), one
out of 11 patients who are 65 years or older die within 30 days of diagnosis of CDI
(CDC, 2017). Mortality rate after 90 days is further increased to 22% (McFarland et al.,
2018, p. 444). For those who do survive, the infection may leave an impact and burden on
one’s physical, mental, and emotional health. In a qualitative study by Guillemin et al.
(2014), the authors conclude that CDI was a traumatic and frightening experience for
patients. One patient describes the fatigue she experienced topped with the
embarrassment of being in an isolation room, she then describes when she returned home,
she could not return to work for a few weeks due to the increased frequency of her bowel
movements. The authors bring light to the burden associated with CDI with hopes that
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the study may encourage providers to take extra precautions to prevent occurrence of the
infection (Guillemin et al., 2014, p. 97).
Despite the CDC’s initiative to promote antibiotic stewardship through decreased
prescribing practices of antibiotic and increased education of modified contact
precautions in the inpatient hospital setting, infection rates remain significant (McFarland
et al., 2018, p. 444). Use of probiotics to support gastrointestinal health has been
speculated for quite some time (Chaturaka, 2018). In a meta-analysis performed by
McFarland et al. (2018), authors note that probiotics helped to restore the intestinal
microbiome and reduced bioavailability which resulted in decreased Clostridium difficile
growth. Additionally, probiotics may neutralize toxins released by Clostridium difficile
resulting in reduced inflammation in the gastrointestinal tract (McFarland et al., 2018, p.
444). The role probiotics play in decreasing bioavailability and in turn decreasing
Clostridium difficile proliferation seems plausible (Lewis, Lundberg, Tharp, & Runnels,
2017, p. 849). However, due to lack of sufficient research, prescriber use of probiotics as
a prophylactic measure to decrease the incidence of CDI remains variable.
Purpose and PICOT Question
The purpose of the integrative literature review was to analyze studies in which
probiotics are used as a measure to prevent CDI, analyze the safety of probiotic
formularies, and determine costs savings related to probiotic implementation. Therefore,
the aim of the review is to determine whether probiotics are safe and beneficial in the
prevention of Clostridium difficile for patients who are receiving antibiotic therapy most
prone to causing CDI. Concurrently, the secondary aim was to determine if there was
evidence that probiotics resulted in cost savings to institutions.
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To effectively perform a review of literature and explore the clinical inquiry, a
PICOT question was formed. PICOT is a format used to develop a clinical question that
guides a review of literature. PICOT is an acronym for the following elements: Ppopulation of interest, I- intervention described, C-comparison for the intervention, Ooutcomes to be measured, and T- timeline (Gray, Grove, & Sutherland, 2017, p. 459).
The PICOT question developed was:
“For adult patients in the hospital setting who receive high risk antibiotics associated with
the development of CDI, (Cefepime, Piperacillin, Ciprofloxacin, Fluoroquinolones,
Vancomycin, Clindamycin, and Cephalosporin); is the practice of prophylactically
administering a Lactobacillus containing probiotic concurrently with a course of
antibiotic treatment compared to no probiotic intervention, a efficacious, safe, and costeffective method to reduce rates of hospital acquired Clostridium difficile infection?”
Method Used for the Inquiry
Systematic and exhaustive search methods were conducted from January 2019November 2019. Six research databases were utilized, including: CINAHL, PubMed,
Cochrane, OVID, EBSCO host, and Google Scholar. Keywords and search terms utilized
were: prophylactic probiotic, Clostridium difficile, antibiotics, patient experience,
probiotics, economic burden, infection reduction, cost analysis, and cost saving. Table
A1. Database Search, delineates the dates of searches, database used, keywords utilized,
and number of hits obtained. All databases that were used were filtered to articles less
than ten years old, printed in English, and had human subjects.
Purpose of the review of literature was to obtain systematic reviews, metaanalysis, and strong randomized control trials to support the above-mentioned clinical
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question. Special attention was made to find studies that examined a probiotic
intervention against a placebo or no intervention, probiotics administered concurrently
with antibiotics, (as a prophylactic measure), and probiotic formularies that contained
Lactobacillus or were multi-strained with Lactobacillus. Primary focus was placed on
finding studies that reported the effects of utilizing probiotics on rates of CDI and
evaluated the safety of probiotics. Secondary focus was placed on studies that evaluated
cost-effectiveness of implementing probiotics in the in-patient hospital setting.
Nineteen articles were reviewed. The SALSA framework, (Search, Appraisal,
Synthesis, and Analysis), was the structural base and process used to guide this scholarly
inquiry project (Grant & Booth, 2009). Critical appraisal of each individual study was
performed utilizing appraisal guidelines described in Gray, Grove and Sutherland, (2007)
text. Articles were scored for their level of evidence guided by: Ackley, Swan, Ladwig,
and Tucker (2008). Hierarchy of evidence description can be viewed in Table B1. Level
of Evidence. By utilizing “SALSA” framework and the critiquing guidelines presented
by Gray et al. (2009), and Ackley et al. (2008), Nineteen studies were noted to be most
useful for the purpose of this review and are included in Tables C1- C19., Literature
Review. For each article critiqued; objectives, evaluation of the sample population,
methods of study design, variables, and measurement tools were noted. Implications and
applicability for practice are described.
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Section II
Literature Review
Introduction
Due to the controversial nature surrounding the topic of probiotic therapy, the
efficacy of probiotics for prevention of CDI has been moderately studied (VandenNieuwboer, & Claassen, 2019). As a result, nine of the nineteen articles examined were
systematic reviews and meta-analyses. Of the remaining articles, one was a qualitative
review, and nine were individual studies ranging from cohort studies to multi-center
randomized control trials.
Several themes emerged following the review of literature. These themes
included: variation in study sampling methods/flaws, variation in interventions, and study
findings. To help guide the reader; a theme matrix may be found in Table D1. Theme
Matrix. This theme matrix was constructed to delineate each individual study with the
matching themes. Each theme was subsequently described in detail in the literature
review section.
Theme One: Study Methods
Study methods concerning sampling flaws, bias, and exclusion of high-risk
patients poses a problem for prescribing providers as confidence in study findings may be
lowered due to these factors. Sampling flaws, selection bias, and presence of
heterogeneity lower the strength of the research findings. The issue of excluding high risk
patients may decrease transferability of study findings into practice. Variability of what is
considered a high-risk patient is high across the studies examined.
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Study heterogeneity and selection bias. Multiple authors of the systematic
reviews, such as Lau and Chamberlain (2016), noted the complexity of ensuring
heterogeneity while maintaining low risk of publication bias. This issue may leave
providers unable to determine the interventions that are most effective in the reduction of
CDI cases. Numerous variations in variables between each randomized control study
poses a problem for systematic reviews and meta-analysis. This variability from study to
study can result in a high level of heterogeneity. Due to the many differences between
studies, the researcher is not able to verify the reliability of the study methods, due to the
lack of replication in study designs.
Three of the nine systematic reviews provided strong evidence to support low
study heterogeneity, low risk of publication, and low selection bias. Johnston et al.
(2012), Lau and Chamberlain (2016), and Shen et al. (2017), do not show any apparent
risk of selection bias and reported statistics of low heterogeneity. This gave these studies
good strength and credibility. These findings suggest that the studies being combined
were alike and the data from the meta-analysis was credible. Low selection bias in these
three studies suggested there was no researcher bias in the selection of the studies that
were included in the analysis.
A meta-analysis performed by the Cochrane group, authored by Goldenberg et al
(2018), reported low risk of publication bias and no significant heterogeneity when
analyzing studies that focused on CDI reduction. However, publication bias was present
when the study focus was switched to adverse events instead of CDI reduction, resulting
in significant level of heterogeneity. This was due to the lack of volume of studies that
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reported adverse events. Therefore, selection bias was eminent and resulted in a
downgrade of certainty of evidence to low (Goldenberg et al., 2017, p. 24).
The remaining five systematic reviews/meta-analysis poorly reported processes of
controlling and analyzing for publication bias and ensuring heterogeneity (Hassan,
Rompola, Glaser, Kinsey, & Philips, 2018; Leal, Heitman, Conly, Henderson, & Manns,
2016; Li et al., 2018; Pattani, Palda, Hwang, & Shah, 2013; Redman, Philips, & Ward,
2014). Both Leal et al. (2016) and Li et al. (2018) did not report any statistics regarding
heterogeneity, nor mention a process to determine publication bias. Hassan et al. (2018),
Pattani et al. (2013), and Redman et al. (2014), vaguely reported presence of moderate
publication bias. Yet, no further statistical values were given to determine the extent of
bias present. Although these studies seem to provide valuable information and statistical
analysis, complete confidence in their value cannot be determined due to these two
factors. This is the biggest flaw of these studies. Through analysis of each individual
study, the complexity of finding a group of individual studies that have similar variables
is apparent. Little to no study replication was found in this review of literature.
Poor sampling methods/study design. When the individual studies were
analyzed, (disregarding systematic review and meta-analysis), all ten of the individual
studies had flaws in sampling methods and study designs. Despite the flaws, each study is
believed to contribute value that can be used for further research.
Seven of the studies were retrospective design studies (Box, Ortwine, &
Goicoechea, 2018; Carvour et al., 2019; Dudzicz, Kujawa-Szewieczek, Kwiecien,
Wiecke, & Adamczak, 2018; Kujawa-Szewieczek et al., 2015; Lewis et al., 2017;
Maziade, Andriessen, Pereira, Currie, & Goldstein, 2013; Sadanand, Newland, &
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Bednarski, 2019). Retrospective designed studies pose the problem of a lack of
randomization. This study method lacks control, as a result, risk factors or extraneous
variables that may contribute to CDI reduction or proliferation may not be measured
(Gray et al., 2017 p. 241). Due to high rates of internal and external threats to validity in
retrospective designed studies, determining cause and effect relationships may be
confounded (Tofthagen, 2012, p. 181). However, there is value to retrospective studies.
These factors include financial feasibility, (compared to large randomized control
studies), and design success and/or failures that can be used for design of further studies
(Tofthagen, 2012, p. 181).
All seven retrospective designed studies were single center cohort studies.
Therefore, external validity, (extent to which research results can be generalized to other
populations), cannot be fully determined. Another downfall of single center studies is
insight to other unmeasured study variables or phenomena, such as differences in
standards of care, cannot be determined unless specifically stated (Gray et al., 2017, p.
199). However, these studies still provide insight that can be useful for further research.
The last two studies by Selinger et al. (2013) and Guillemin et al. (2014), had
sampling flaws. The Selinger et al. (2013) study, despite being a strong randomized
control trial with good rigor, had a low power analysis. The power required for adequate
sample size was calculated to be greater than 382 participants; the final number of
participants was 122 (Selinger et al., 2013, p.161). Selinger et al. (2013) initially did have
a higher total population sample (initial enrollment was 231). The study had a poor
attrition rate resulting in a final study sample of 122 patients. This was lower than the
required power analysis set at five percent level of significance.
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Lastly, Guillemin et al. (2014) performed a qualitative study on the mental,
physical, and emotional impact associated with the diagnosis of CDI. In this study,
sampling methods initially were purposive. However, a portion of the sample population
ended up being recruited under convenience sampling. The initial study was designed to
control for selection bias by having a third-party agency enroll patients. Yet, a clinician
who was involved directly with this patient population, helped to recruit patients
(Guillemin et al., 2014, p. 99).
These examples convey the need for further randomized control trials that are
large enough to meet a power analysis of five percent level of significance, have rigor in
sample selection methods, and have strong control on variables. Once high-quality
individual studies are performed and further replicated, systematic reviews and metaanalysis will then have less significant levels of heterogeneity between each individual
study analyzed. In turn, the lower level of heterogeneity may provide researchers higher
confidence in the meta-analysis findings.
Exclusion of high-risk patients. Many of the studies analyzed excluded “high
risk” patients due to concerns for risk of adverse events. For each of these studies the
definition of high risk varied. Variability of “high risk” poses a problem for providers
when analyzing these studies. Exclusion of high-risk patients may also decrease a
provider’s ability to apply the concepts of the research into clinical practice. Determining
the risk versus benefit ratio of probiotics for high-risk patient groups is difficult, due to
lack of studies that include high risk patients. Probiotics may be safe and hold benefit for
these high-risk patient population groups. A few studies found within this literature
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review did include a high-risk population sample, such as the article by Dudzcicz et al.
(2018).
Several studies report exclusion of high-risk patients (Lau and Chamberlain,
2016; Lewis et al., 2017; Pattani et al., 2013; Selinger et al., 2013; Shen et al., 2017).
Each study’s definition of high risk is defined differently. For example, Shen et al. (2017)
defined “high risk” as: pregnancy, human immunodeficiency virus, previous organ
transplant, undergoing chemo-therapy and/or radiation, prosthetic heart valves, admitted
to an intensive care unit for any reason, and pre-existing gastrointestinal disorders of any
type (Shen et al., 2017, p. 1891). Lewis et al. (2017) reported an exclusion of high-risk
patients similar to Shen’s except the addition of the presence of a central venous catheter
and unable to take medications orally (Lewis et al., 2017, p. 849). Both exclusion criteria
are similar, yet different, leaving the high-risk exclusion criteria unclear. Of these five
studies that do not include high risk patients, all have findings which supported the use of
probiotics, but state that further research is needed due to study limitations.
Several studies in this review did contain high-risk patient populations (Dudzicz
et al., 2018; Hassan et al., 2018; Kujawa-Szewieczek et al., 2015; Maziade et al., 2013;
Redman et al., 2014). These studies focused on high-risk patient population groups or
included high risk patients. All five of the studies were based outside of the United
States, however, were still in well-developed countries. For example, the study by
Maziade et al. (2013), was performed in Quebec, Canada and included patients that have
been excluded from prior Canadian randomized control trials for the following: recent
chemotherapy use, presence of cardiac valves, patients within the intensive care units,
and presence of central venous catheters (Maziade et al., 2013 pp. 1342-1343). The study
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by Dudzicz et al. (2018) is based in a nephrology and post transplantation ward. In the
Dudzicz et al. (2018) study, all the post-transplant patients were receiving
immunosuppressive medications, resulting in an immunocompromised state. No
significant adverse side effects, bacteremia or fungemia related sepsis, linked to probiotic
administration were found in these studies.
The culture of not prescribing probiotics to “high-risk” patient populations comes
from multiple individual case studies citing the link of probiotics to sepsis. However, a
recent systematic review by Costa et al. (2018) noted a lack of significant evidence to
support this practice. Costa et al. (2018) performed a systematic review and meta-analysis
of individual clinical reports and case studies related to serious effects related to
Lactobacillus probiotic usage. The author found that there have been a total of 93 cases of
septicemia and/or fungaemia related to all probiotic species types since 1976-2018 and of
those 93 cases 26 were related to Lactobacillus probiotics since (Costa et al., 2018, p. 4).
Studies analyzed within this review of literature, (19 articles, of which nine are
systematic reviews), did not note any patients who experienced major adverse health
events related to Lactobacillus administration. This leaves the provider questioning if
such stringent inclusion criteria are necessary or if adequate research has yet to be
performed.
Theme Two: Intervention Methodologies
High variability in intervention practices was an emerging theme in this review.
Every study had differences in species, concentration/dosage, timing of initiation, and
duration of the probiotics administered. This impedes providers from utilizing the highest
evidence in practice. Determination of which strain, concentration, and timing of
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administration was most beneficial for reducing CDI outcomes was unclear, due to lack
of rigor within studies and lack of replication of studies.
Probiotic species and dosage. Based on recommendations by the Cochrane
group, the aim of the article review was to use studies that focused on probiotics that
contained Lactobacillus (Goldenberg et al., 2017, p. 23). This was a difficult goal as
many of the systematic reviews included different types of probiotic strains such as
Bifidobacterium, and Saccharomyces boulardii. Even with studies that only focused on
Lactobacillus probiotics, high variability across all the studies in concentration/colony
forming units per dosage, and dosing frequency, were found. Once again, this factor was
a major contributor to the high heterogenicity seen within all the systematic reviews.
Many of the systematic reviews did not control specifically for the species type
and dosage of the probiotics. For example, the systematic review by Hassan et al. (2018),
performed statistical analysis of pooled data from 25 studies, in which the main
population studied was cancer patients. Eighteen of the 25 studies reviewed contained a
Lactobacillus probiotic. The results of the study appeared promising in the efficacy of
probiotics. Yet, the authors disclosed that no conclusion of probiotic safety and efficacy
could be determined due to the vast interventional heterogeneity present in the studies
(Hassan et al., 2018, p. 2509). This was a common phrase and theme found in many of
the systematic reviews. Goldenberg et al. (2018), Hassan et al. (2018), Johnston et al.
(2012), Lau and Chamberlain (2016), Leal et al. (2016), Li et al. (2018), Pattani et al.
(2013), Redman et al. (2013), and Shen et al. (2017), all lacked rigor in their intervention
design in regards to probiotic species and dosing frequency, and do not exclusively use
probiotics containing Lactobacillus. In the study by Pattani et al, (2013), authors
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researched multiple probiotic species but only the probiotics which contained a
Lactobacillus species showed significant reduction in CDI (relative risk of 0.33, risk
difference -.010, CI [-.5-.05] I² = 0.) (Pattani et al., 2013, p. e64).
Box et al.’s (2018) retrospective cohort study attempted to control variability by
only analyzing patients who received a probiotic formulation (which contained
Lactobacillus), called “Bio-K”. Yet, because probiotic prescribing was left to the
digression of the primary provider, high variability in dosage amount and frequency of
dosing was found. As a result, high degree of prescribing bias was present (Box et al.,
2018, p. 2). There was a chance that only patients who providers believed were high risk
for CDI were prescribed the probiotic. Due to the lack of a control group, confidence in
the study findings are low.
Seven of the articles reviewed controlled the intervention by using a specific type
of probiotic, all which contained Lactobacillus, these articles also specified the dosing
amount and frequency (Dudzcicz et al., 2018; Kamdeu et al., 2012; Kujawa-Szewieczek
et al., 2015; Lewis et al., 2017; Maziade et al., 2013; Sadanand et al., 2019; Selinger et
al., 2013). For example, Dudzcicz et al. (2018), had a strong designed study with high
rigor. This study analyzed CDI outcomes for patients in a nephrology and transplantation
unit by administering a Lactobacillus containing probiotic called “LP299v”. The
probiotic was administered orally, once daily, at the start of antibiotic administration, and
continued for the duration of the antibiotic treatment. Due to the high quality of the study,
Dudzicz et al. (2017) may be a landmark study to guide further research.
Timing of probiotic administration. Timing of the administration of probiotics
appeared to be an important factor on the effects of CDI reduction (Shen et al., 2017).
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Within this review, there was high variability between studies on when interventional
probiotics were administered. From analysis of the articles research it appeared the closer
probiotics were started to the time of the initial antibiotic administration, the better the
outcome in reference to CDI reduction (Shen et al.,2017).
The effects of timing on probiotic administration and duration of treatment for
CDI rates were analyzed by Shen et al. (2017). They reported statistically significant
reduction in CDI rates in patients who received probiotics within one to two days of
antibiotic administration, (relative risk 0.32, 95% CI .22-.48), compared to patients who
received probiotics within three to seven days, (relative risk .70, 95% CI .40-1.23). This
resulted in a significant difference in infection rates (p = .02), (Shen et al., 2017, p. 1896).
Understanding of how probiotics work, and how antibiotics disrupt the micro bacterial
state of the gastro-intestinal tract, this concept of starting a probiotic near the start of an
antibiotics seems reasonable (Pattani et al., 2013, p. e65). Seven studies were clear on
their probiotic initiation and administration time frame: Dudzicz et al. (2018), KamdeuFansi et al. (2012), Kujawa-Szewieczek et al. (2015), Lewis et al. (2017), Maziade et al.
(2013), Selinger et al. (2013) and Shen et al. (2013), all initiated probiotics either at the
time of antibiotic administration or within three days of antibiotic start.
One large well-designed randomized control trial called the PLACIDE study by
Allen et al. (2013), failed to initiate a probiotic intervention in a timely manner. This
study found lowered but not significant findings on probiotic efficacy in reducing CDI
rates. However, in the study’s intervention process probiotics were initiated up to seven
days after antibiotic start. Therefore, when implementing Shen et al.’s (2017) findings to
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this study, the timing variable alone could be one of the factors as to why probiotics did
not significantly reduce CDI rates within this study.
Information on timing/ initiation of probiotics was not always included in the
studies. This is problematic as this variable appeared to be an important factor on the
efficacy of probiotics. More research is needed to determine when the administration of
probiotics results in the highest benefit. In this review, probiotics started at the time of
first antibiotic administration and up to two days after seemed to hold the most benefit in
significant reduction of CDI (Dudzicz et al., 2018; Kamdeu-Fansi et al., 2012; KujawaSzewieczek et al., 2015; Lewis et al., 2017; Maziade et al., 2013; Selinger et al., 2013;
Shen et al., 2013).
Theme Three: Findings
Returning to the main purpose of the review; the efficacy of probiotics on
reducing the rates of CDI in hospitalized patients undergoing antibiotic therapy,
determining if they are cost effective, and safe. As noted with the previous themes
discussed, there are many hinderances in both the background methods and interventional
methods that make a final conclusion on the efficacy and safety of probiotics difficult.
However, in this literature review, Lactobacillus probiotics appeared to have a positive
effect on reducing CDI rates, appeared to be cost-effective, and do not seem to have more
adverse events/side effects than a control or placebo intervention.
Decreased Clostridium difficile infection rates. Twelve out of the 16 studies that
had an outcome measure analyzing the effect of probiotics on CDI rates, provided
evidence to support the use of probiotics as a means of CDI prevention. However, due to
the many flaws previously mentioned in this review, most of the studies disclose that

18

future studies are needed to fully support the use of probiotics with high confidence. The
lack of rigor and poor study designs leave the validity of the research findings unclear.
Goldenberg et al. (2018), which is considered a landmark study on the subject of
probiotic efficacy, found prophylactic probiotics are effective but most useful in hospitals
in which preintervention rates of CDI is greater than five percent. In environments with
baseline CDI rates greater than five percent, the implementation of probiotics may result
in a 70% risk reduction (Goldenberg, et al., 2018, p. 19). Among the other studies that
were of moderate quality, the average risk reduction of CDI ranged from 33-40% with an
average of 35.6% reduced risk of CDI (Johnston et al., 2012; Leal et al., 2018; Pattani et
al., 2013; Shen et al., 2017).
Although the article by Dudzicz et al. (2018) was a retrospective single center
study, their design had high rigor, (in terms of dosing, timing of administration and
duration of probiotic treatment). Their inclusion of high-risk patient population and rigor
within the study design, may make this study a future landmark study. Their findings
showed a significant decrease in rate of CDI during the implementation period of a
Lactobacillus containing probiotic called “LP299v” administered once per day with the
start of any antibiotic. The incidence rate of CDI declined from 10.3 cases per 1,000
patients, down to 1.1 cases per 1000 patients, (p = 0.0003). This was a significant finding.
When researchers discontinued probiotics in phase three of their study, CDI rates again
increased and matched preintervention rates (Dudzicz et al., 2018, pp. 5-7). Despite study
flaws and poor designs seen within many of the studies, probiotics consistently seem to
be effective as a prophylactic measure for CDI reduction (Butler et al., 2016, p. 21). The
Cochrane hand book discusses study designs and lack of study replication to be the major
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reason for why they termed evidence of probiotic efficacy as moderate quality
(Goldenberg et al., 2017, p.5).
The studies that do not support probiotics as a CDI reduction method also have
many flaws. For example, high prescriber bias, was seen in the study by Box et al.
(2018), where probiotic prescribing was left solely to the digression of the prescribing
provider. This further supported that probiotics may be efficacious when noting the
quality of the studies that did not support probiotics had lower appraised quality than
their counter part. However, the lack of overall quality, rigor, and heterogeneity between
studies leaves the researcher unable to state with high level of certainty that probiotics are
effective. Due the study design flaws, this research review finds that probiotics are likely
effective for reducing CDI rates, but only can be concluded with a low to moderate level
of certainty due to poor study design.
Cost effectiveness. Cost effectiveness was an important finding to analyze. Cost
effective analysis is often needed to gain support from stakeholders in a hospital setting
(Melnyk & Fineout-Overholt, 2015, p.474). Six studies discussed the cost related savings
and benefits of using probiotics. Dudzicz et al. (2018), Kamdeu et al. (2012) and Li et al.
(2018), provided the most evidence of cost savings in this literature review.
Dudzicz et al. (2018) performed a study in which patients in a nephrology and
transplantation ward received a probiotic called “LP299v” orally, once per day. The
result was a decrease in CDI rates from 10.3 per 1,000 patients to 1.1 cases per 1,000
patients, (p = 0.0003) (Dudzicz et al., 2018, p.5). Cost to implement a probiotic as a
prophylactic measure, for an average of 14 days was about four dollars and fifty cents.
Utilizing the number needed to treat, which was 15, the cost to prevent one case of CDI
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was about 68.9 dollars. This is a significant finding, as one case of CDI can cost an
average of 8,000 dollars to treat (Dudzicz et al., 2018, p. 9).
Kamdeu-Fansi et al. (2012) performed a formal cost benefit analysis on a study
that was previously performed by Gao et al. (2010). Despite the study being originally
performed in China, Kamdeu-Fansi et al. (2012) performed adjustments for the
differences in currency value to match costs of American pharmaceuticals and hospital
products. They performed this by utilizing the American Consumer Price Index to
determine the cost adjustments. In the study there were three cohorts; one placebo group,
one group who received one “Bio-K+” probiotic daily, and one group that received two
capsules of the “Bio-K+” probiotic, once per day. The authors made five major
assumptions based on typical care practices. They assumed CDI testing would be
performed by a microbiological screening test. They assumed, after CDI diagnosis, 58%
of patients would be treated with Metronidazole and 42% would receive Vancomycin.
They assumed Metronidazole would fail in 26% of the cases (based off current literature
findings). They also assumed that patients with CDI would have a prolonged length of
hospital stay (Kamdeu-Fansi et al., 2012, pp. 56-57). For cohort one (placebo), they
found an average additional length of hospital stay was six toseven days. Cohort two
average hospital length of stay was four days, and cohort three average length of hospital
stay was two to three days. For those who were diagnosed with CDI, the additional
hospitalization costs were about 1,424.16 dollars per day (Kamdeu Fansi et al., 2012,
p.56). Therefore, utilizing these assumptions and study findings, if all patients who are at
risk of CDI are given one probiotic once per day, due to the subsequent decrease in total
CDI cases, the total cost savings may result in 1,968 dollars per patient given the Bio-K+
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probiotic. In the scenario for those who received two capsules of the Bio- K+ probiotic,
the cost savings were closer to 2,661 dollars, per patient treated with the probiotic
(Kamdeu-Fansi et al., 2012, p. 56). Utilizing the average CDI rate per 1,000 patients in
American hospitals, prophylactically treating 1,000 patients with two capsules of
probiotics, once per day, during their antibiotic course, could result in a cost savings of
1,680,000 dollars annually (Kamdeu-Fansi et al. (2012, p.59). This study was based
solely on hospital costs and did not take into account quality of life cost adjustments.
Li et al. (2018) also analyzed in-hospital costs but adjusted the analysis to include
burden on quality of life indicators. Li et al. (2018) suggest cost savings to an institution
was higher when taking into consideration the quality of life effects. They reported
savings were closer to 3,686 dollars per patient treated with probiotics due to the
decreased overall rates of CDI and decreased quality of life burden (Li et al., 2018, p.
473).
These findings are highly significant when discussing cost savings to an
institution. Each case of CDI was associated with increased length of hospital stay,
increased need in medical cares, and increased mortality rates. Quality of life adjustments
with this infection are equally important to consider. In a qualitative study by Guillemin
et al. (2014), authors explored the perceived burden associated with CDI from the
patient’s lived experience. They highlight that the diagnosis and symptoms associated
with CDI were highly burdensome and found data saturation on the negative effects the
infection had on psychological and emotional health of patients. They find increased
negative effects on an individual’s professional life and an increased financial burden
experienced by the patients. The financial burden experienced was mostly due to
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increased required payment for hospital services and additional time off work that was
required post hospital discharge (Guillemin et al., 2014, p. 100). The article was an
excellent example of how healthcare associated costs to a facility are not the only aspects
to consider when a cost-benefit analysis is performed. Quality of life measurement
continues to be an important aspect to consider in an analysis of cost versus benefit (Li et
al., 2018). As shown in the Guillemin et al., (2016) study, CDI affected patients’ lives
due to the increased length of hospital stay, increased embarrassment felt by the patient,
and financial implications due to lost time at work (Guillemin et al., 2016).
Adverse side effects. The last finding analyzed was to determine if there were
significant differences in adverse side effects with the use of an interventional
Lactobacillus probiotic group compared to a placebo group. This was a very important
variable to determine for future studies as implementation of an intervention that is
known to be harmful to a patient would be unethical. As noted in the exclusion of highrisk patient section, there is hesitancy to use probiotics on patients due to a concern for
increased chance of blood stream infections related to probiotic use. This practice was
based off individual clinical reports and case studies. Again, according to Costa et al.
(2018) there was significant lack of evidence to support this practice. Six studies were
included in this review based on their inclusion of “high-risk” patients. All six of the
studies found no significant difference in adverse effects related to a probiotic group
versus a placebo group.
Hassan et al. (2018) focused on a sample population group with cancer. They
found that adverse events in the intervention group (n = 237) were lower than that in the
control group (n = 314) (Hassan et al., 2018, p.2506). Hassan et al. (2018) did not
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provide a statistical analysis to determine if this finding was significant. However, their
inclusion of the high-risk patient population is important to note. Sadanand et al. (2019)
performed a single -center retrospective study on pediatric hemopoietic stem cell
transplant patients. These patients received a Lactobacillus containing probiotic as a
treatment method for graft versus host disease. No cases of blood stream infections while
patients were on probiotics were found. (Sadanand et al., 2019, p. 304). Although this
study did not exclusively look at CDI infection, the study is included as an important
supporting factor for the safety of probiotics. These post transplantation pediatric patients
were receiving immunosuppressive medication. Yet, there were no severe adverse events,
such as probiotic related septicemia, seen in this study related to probiotic usage
(Sadanand et al., 2019, p. 305).
Goldenberg et al. (2018), Johnston et al. (2012), and Shen et al (2017) all
performed analysis on adverse event variables and provided statistical data to support
their findings. Goldenberg et al. (2018) found statistically significant data which
supported less adverse side effects in the probiotic group over placebo. However, due to
the high publication bias present within the systematic review and meta-analysis, this
study’s findings were inconclusive (Goldenberg et al., 2018). Johnston et al. (2012),
found when comparing the adverse events in a placebo group versus a probiotic treatment
group, there was a relative risk reduction of 0.82, with a 95% confidence interval of 0.651.05. Thus, the authors supported the safety of the probiotic intervention. The authors
noted the evidence classified as moderate quality evidence (Johnston et al., 2012, p. 884).
Shen et al. (2017) stated there was no significant difference in adverse effects from the
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placebo group to intervention group (p = 0.35), in their study (Shen et al., 2017, pp.
1894-1895).
Literature Review Summary
The efficacy of probiotics remains unclear. There likely is benefit to the use of
probiotics as a prophylactic measure to reduce CDI occurrence within the hospital
setting. The main hinderance to this subject’s clarity is the lack of strong study methods
and backgrounds and high heterogeneity between many of the studies analyzed within the
systematic reviews analyzed. Individual studies lacked rigor and randomization. This
conclusion was consistent with findings and recommendations posted by the Agency for
Healthcare Research and Quality (AHRQ), Comparative Effectiveness Review. They
listed probiotics as a treatment option with low quality of evidence but consistent
findings of efficacy (Butler et al., 2016, p.21). They also found the prevention methods:
antibiotic stewardship and handwashing, to also have low quality of evidence. Other
measures such as chlorhexidine bathing, ultraviolet room cleaning, and hydrogen
peroxide cleaners, do not have sufficient evidence to support these practices as evidencebased methods (Butler et al., 2016, p. 15). Therefore, Butler et al. (2016) argued that the
low quality of evidence should not rule out usage of probiotics as antibiotic stewardship
and handwashing continues to be a widely accepted hospital practice.
A theme noted in many of the studies was exclusion of the high-risk patient
population. This concept stemmed from a few case studies where blood stream infections
were believed to be from the use of a probiotic. A compelling article by Costa et al.
(2018) found this concept to be rare and not a reliable reason to exclude high risk
patients. Multiple articles within this review were selected due to their inclusion of a
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high-risk population group- such as stem cell transplantation patients and cancer patients.
No adverse events were found in any of the studies contained within this review of
literature. Therefore, in order to strengthen support for the use of probiotics more highquality randomized controls studies that have rigor and high control need to be performed
and less stringent exclusion criteria may need to be considered.
Within this review, a few intervention methodologies were sought including a
probiotic intervention that contained Lactobacillus, and studies that analyzed the effect of
the timing of initiation of a probiotic. The concept of focusing on studies that contain a
Lactobacillus component was guided by current recommendations from the Cochrane
group (Goldenberg et al., 2017). Studies that analyzed the effect on the timing of
probiotic administration noted higher success with CDI reduction when a probiotic
intervention was initiated within three days of antibiotic administration (Dudzicz et al.,
2018; Kamdeu-Fansi et al., 2012; Kujawa-Szewieczek et al., 2015; Lewis et al., 2017;
Maziade et al., 2013; Selinger et al., 2013; and Shen et al., 2013).
Overall findings for the initial PICOT question are difficult to answer due to the
study flaws previously mentioned. Therefore, overall support for the use of probiotics is
supported within this review with only low to moderate confidence. This matches the
current Cochrane handbook’s consensus of their review of the literature (Goldenberg et
al., 2017). They too noted the quality of evidence to support the use of probiotics as a
preventative measure for CDI as “moderate”. The AHRQ noted the evidence for use of
probiotics as low but was consistently effective for reduction of CDI rates. The low rating
was due to high heterogeneity between studies analyzed (Butler et al., 2016, p.121).
Twelve of the 16 studies reviewed showed reduced incidence of CDI rates when a
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probiotic treatment was implemented. Of the remaining four articles, two did not support
the use of probiotics (Box et al.,2018; Carvour et al., 2019). These two studies had
severely flawed study methods which rendered the quality of the studies as low. The
remaining two articles suggested reduction in cases of CDI; however, findings were not
statistically significant (Johnston et al., 2012; Li et al., 2018).
Cost effectiveness of probiotics is supported by this review of the literature. Cost
savings could be as high a 2,661 dollars per patient treated with a probiotic as a
prophylactic measure (Kamdeu-Fansi et al., 2012, p. 56). This finding was due to the
resultant overall decrease in hospital acquired cases of CDI (Kamdeu-Fansi et al., 2012,
p. 56). Utilizing the average CDI rate per 1,000 patients in American hospitals, the
implementation of treating 1,000 patients with two capsules of probiotics once per day,
during their antibiotic course, may result in a cost savings of 1,680,000 dollars (KamdeuFansi et al., 2012, p. 56).
No significant difference in adverse effects experienced by a probiotic
intervention group over a control group was found in this literature review. Inclusion of
studies with high risk patients was performed to aid in analyzing the safety of probiotics
(Dudzuczet al., 2018; Hassan et al., 2018, Kujawa-Szewieczek et al., 2015; Mazaide et
al., 2013; Reman et al., 2014; Sadanand et al., 2019). No major adverse events were
found in the high-risk population groups that were exposed to probiotic treatment. These
compounded findings support the safety of the use of probiotics.
Overall, the literature contained within this review supports the use of a
Lactobacillus containing probiotic when initiated within three days of antibiotic start, as a
measure to reduce CDI incidence within a hospital setting. The evidence within this
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review supports probiotics as a safe and cost-effective measure to reduce Clostridium
difficile incidence within the hospital setting. Due to the flaws within each study
confidence in these findings can only be rated as low to moderate. However, as stated by
Goldenberg et al, (2018) probiotics have the highest quality evidence among cited
prophylactic therapies including handwashing, daily room cleaning, contact isolation, and
antibiotic stewardship, yet are not included in prophylactic clinical practice guidelines
(Goldenberg, et al., 2018, p. 21) Yet to move forward, support for further high-quality,
large, randomized control trial research is needed before institutional prescribing
guidelines can be formulated.
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Section III
Conceptual Framework
Introduction
A conceptual framework was constructed to aid readers to better understand the
phenomenon of interest- Lactobacillus probiotics. As can be viewed in Table E1.
Conceptual Analysis Components, the concept of interest was identified, antecedents and
consequences are explained, and the level of evidence, (which was used to support this
framework), was provided. The purpose of the pictorial framework provided in Figure 1.,
was to provide visual explanation of how each of the variables related to one another and
show the consequential relationship or outcome of the concept.
Relationships Identified
As can be viewed in Figure 1., a negative relationship was seen for the variables
of Clostridium difficile infection rates. This indicates that as the concept of interest is
implemented (a Lactobacillus containing probiotic), rates of CDI are decreased, (Dudzicz
et al., 2018; Goldenberg et al., 2018; Johnston et al., 2012; Kamdeu Fansi et al., 2012;
Kujawa-Szewieczek et al., 2015; Lau & Chamberlain, 2016; Leal et al., 2016; Lewis et
al., 2017; Li et al., 2018; Mazaide et al., 2013; Pattani et al., 2013; and Shen et al., 2017).
When probiotics were administered there was neither a positive or a negative
relationship seen in terms of adverse events. There was no significant difference seen
between the control or intervention group (Goldenberg et al., 2018; Hassan et al., 2018;
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Johnston et al., 2012; Kujawa-Szewieczek et al., 2015; Lau & Chamberlain, 2016;
Mazaide et al., 2016; Redman et al., 2014; and Sadanand et al., 2019).
The final consequence examined was cost versus benefit. As the concept of a
Lactobacillus probiotic was implemented, there was a positive relationship on
institutional cost savings (Dudzicz et al., 2018; Hassan et al., 2018; Kamdeu-Fansi et al.,
2012; Leal et al., 2016; Lewis et al., 2017; Li et al., 2018; Shen et al., 2017).
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Section IV
Conclusions/Recommendations, and Implications
Introduction
Heath care acquired CDI is a highly virulent bacterial infection associated with
increased patient mortality rates, increased costs to hospitals, and an increased burden on
a patient’s overall quality of life (Center for Disease Control, 2017; Guillemin et al.,
2014). Strategies that are known to decrease the incidence of CDI should be examined.
Probiotics utilized for the prevention of CDI has been highly speculated and remains a
controversial topic in healthcare (Vanden-Nieuwboer & Claassen, 2019). This literature
review, aimed to investigate the effects probiotics have on reducing incidence of CDI in
patients who were hospitalized and on antibiotics, whether the probiotic intervention was
safe, and if a probiotic intervention was cost effective. Nineteen total studies were
examined and critiqued for their credibility and quality. Several concepts emerged within
the literature review including flaws in study design, high heterogeneity, presence of
selection bias, and significant variability in intervention methodologies (concerning
species, dosage, duration, and initiation of probiotic). Analysis of study findings suggest
there is a low to moderate effect of a probiotic on CDI reduction, no evidence of adverse
effects related to probiotic usage compared to placebo or no intervention, and data
supporting institutional cost savings related to probiotic implementation. However, due to
the lack of replicated studies and lack of data to support specific prescribing practices,
more research is warranted. Until then prescribing practices should be left to the
discretion of the prescribing provider, who should consider patient preference, and weigh
benefits and risks with use as on a case to case basis.
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Conclusions
Overall, the literature contained within this review supported the use of a
Lactobacillus containing probiotic when initiated within three days of antibiotic start, as a
measure to reduce CDI incidence within a hospital setting. This can only be stated with
low to moderate certainty due to the high heterogeneity seen within most of the
systematic reviews and poor methodology and study design seen within individual
studies.
The evidence supported probiotics as an effective measure to reduce Clostridium
difficile incidence within the hospital setting. Despite many studies excluding high-risk
patients, the articles which did include high risk patients did not find any significant
evidence of an increased risk for adverse events. The concept of excluding high risk
patients may be an outdated theory based on a small volume of case studies suggesting
septicemia related to probiotic usage. This topic should be further addressed with more
research.
The cost-benefit analysis of probiotics and the savings to an institution seemed
promising. When adding in a patient’s quality of life measures, support for the use of
probiotics was further increased. There is hope that the potential financial savings from
this intervention will be appealing to many institutions. Ideally as a result, support for
further research within the institutions should occur and be funded.
During the literature review process and analysis of the current evidence, links to
implications for nursing and advanced nursing practice were addressed, probiotics may
be a safe and inexpensive way to further decrease incidence of CDI. As antibiotic
resistance becomes more prominent within the world, , further treatment and preventative
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aspects of care need to be considered. Further research is needed on dosage, length of
treatment. And the use of probiotics in high risk patient populations. The practice of
including high risk patients in current studies is relatively new and studies that have been
performed lack a strong design and quality.
Implications and Recommendations
Studies focused on probiotics will continue to emerge with new evidence in the
coming years. As advance healthcare providers, keeping up to date on the emerging
evidence will be important. As bacteria and viruses continue to evolve and become more
resistant, the increased risk of hospital acquired CDI needs to be evaluated and measures
to combat infection prevalence need to be taken.
For now, a full institutional change to support routinely prescribing probiotics to
patients on antibiotics is not supported. However, prescribing of a Lactobacillus probiotic
to an average risk patient who is taking antibiotics would not be against the current
evidence. Recommendations for the optimal probiotic prescription: the frequency, dosing,
and duration of the prophylactic treatment is not clear in the evidence. At this time,
providers should practice their critical thinking skills as well as right to autonomy and
prescribe probiotics on a case to case basis. Consideration of patient preference should be
included. Patients that are offered a probiotic supplement should be educated on the risks
of taking a probiotic and the risks associated with not taking a probiotic. Again, the risk
versus benefits, would be based on each patient’s clinical presentation and state of health.
Providers and all healthcare workers should continue to use accepted strategies to prevent
CDI infection in the hospital setting including proper hand hygiene, antibiotic
stewardship, and contact isolation measure for patients diagnosed with CDI.
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To advance the current evidence, advanced practice nurses and providers should
provide the current research findings and flaws to hospital stakeholders with hopes that
funding for more rigorous research will occur. Further research should be based off
strengths of previous studies. Future studies should have a strong control on variables and
detailed explanation of the research process. Ideally, a double-blind randomized control
trial utilizing multiple hospital institutions should be performed. Within all of these
institutions. the same brand, dosage, and frequency of administration, and initiation of the
probiotic or placebo should be completed. Study expectations should be clear on
prescribing goals and probiotics should be initiated within three days of antibiotic start.
The method and practice for testing CDI should be uniform, and current institutional
standard of practice for infection prevention, pre-intervention should be similar. A
universal reporting protocol should be in place to report adverse events with the probiotic
use.
Once further research is completed, if the evidence supports the use of probiotics
with high confidence, hospital stakeholders should be re-engaged to determine if an
intuitional change will be supported. If change is supported guideline development and
education to prescribing providers should be performed. Guideline development and
clinical decision support tools which could flag a provider that a probiotic should be
considered when high risk antibiotics are prescribed, would be helpful. Once again, these
would only be indicated once more rigorous and precise research is performed and if the
research obtained supports the use of probiotics.
At this time, providers are recommended to remain current on emerging evidence
related to the use of probiotics. Critical thinking skills and autonomy should be utilized to
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weigh the benefits versus risk of using probiotics on case to case basis. As always, patient
preference should be determined, and patients should be educated on the benefits versus
risk of using a probiotic supplement.
Summary
Research contained within this review of literature supports the use of probiotics
administered concurrently with antibiotics as a prophylactic measure to prevent CDI in
the hospital setting with moderate certainty. Evidence supports that probiotics have low
associated risk with usage for those who are not immunocompromised. Cost savings is
apparent within the studies analyzed. However, due to high heterogeneity seen between
each individual study and lack of study replication, confidence in these study findings is
low to moderate.
At this time providers should engage in reviewing emerging evidenced based
research that emerges. Consideration for the use of a probiotic supplement should be
gauged on a patient to patient basis and risk versus benefit of probiotic usage should be
analyzed. As with any care provided, patient preference should be analyzed. Patients
should be educated on the benefit and risks associated with the usage of a probiotic
supplement, as well as, the risk associated with not utilizing the supplement.
Advanced practice providers should continue to be at the forefront of pursuing
research. Once further high-quality research with high rigor is performed, data found
within those studies can be used to support or not support an institutional change. Until
then, all healthcare providers should continue to practice universal infection control
measures and CDI prevention methods specified by his/her individual institution and
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providers should use critical thinking and autonomy to determine the benefits versus risk
of prescribing a probiotic to patients on a case to case basis.
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Table A1.
Clinical Definition and Recommended Treatment for Clostridium difficile Infection in Adults
Clinical Definition Signs/Symptoms
Recommended Treatment Methods
Initial Episode- Mild

Leukocytosis less than 15,000. Serum
creatinine less than 1.5mg/dL

Initial Episode
Moderate

Leukocytosis greater than 15,000
Creatinine greater than 1.5mg/dL

Initial Episode Severe

Leukocytosis greater than 15,000
Creatinine greater than 1.5mg/dL
Hypotension, shock, ileus, mega colon

First Recurrence

Second Recurrence

First line treatment: Vancomycin 125mg every six hours for ten days.
Or
Fidaxomicin 200mg twice per day for ten days
If neither Vancomycin or Fidaxomicin are available: Metronidazole 500mg three
times per day for ten days.
First line treatment: Vancomycin 125mg every six hours for ten days.
Or
Fidaxomicin 200mg twice per day for ten days
Vancomycin 500mg every six hours via mouth or nasogastric tube.
If ileus is present add rectal instillation of Vancomycin 500mg every six hours
AND
Intravenous Metronidazole 500mg every eight hours
If Metronidazole was used for first episode: Vancomycin 125mg every six hours
for ten days
Or
Prolonged taper of Vancomycin 125mg every six hours for 10-14 days then
125mg twice per day for seven days, then once per day for seven days, Lastly
once every three days for two to eight weeks
Prolonged taper of Vancomycin (see above)
Or
Vancomycin 125mg every six hours for 10 days followed by Rifaximin 400mg
three times daily for twenty days
Or
Fidaxomicin 200 mg twice per day for ten days
Or
Fecal microbiota transplantation

Referenced from: McDonald et al. (2018)
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Table B1.
Database Search
Date of
search
1/29/19

Key Words Used

Prophylactic Probiotic and
Clostridium difficile and
Antibiotics
2/6/19
Clostridium difficile, Probiotics,
Hospital
2/20/19 Patient Experience and
Clostridium difficile
3/1/19
Probiotic, Clostridium difficile
3/10/19 Probiotic
3/10/19 Economic Burden, Clostridium
difficile
3/12/19 Probiotics, Reduce, Clostridium
difficile
3/15/19 Cost Analysis, Probiotics, Reduce
Clostridium difficile
3/19/19 Cost, Probiotics, Clostridium
difficile
10/23/19 Probiotics and Clostridium
difficile
11/1/19 Cost Effectiveness, Probiotics
11/15/19 Safety, Probiotic
11/27/19 Probiotic, Immunosuppression

Database used

Listed

Reviewed

Used

CINAHL

18

14

1

PubMed

44

15

2

CINAHL

36

3

1

Cochrane
OVID
PubMed

23
2
112

1
2
4

1
0
1

Google Scholar

1989

2

0

Cochrane

2

1

1

PubMed

14

3

1

EBSCOhost

214

9

3

PubMed
CINAHL
PubMed

36
194
2

4
20
1

2
3
1
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Table C1.
Level of Evidence Key
Level of evidence
(LOE)
Level I

Description
Evidence from a systematic review or meta-analysis of all relevant RCTs (randomized
controlled trial) or evidence-based clinical practice guidelines based on systematic reviews of
RCTs or three or more RCTs of good quality that have similar results.
Level II
Evidence obtained from at least one well-designed RCT (e.g. large multi-site RCT).
Level III
Evidence obtained from well-designed controlled trials without randomization (i.e. quasiexperimental).
Level IV
Evidence from well-designed case-control or cohort studies.
Level V
Evidence from systematic reviews of descriptive and qualitative studies (meta-synthesis).
Level VI
Evidence from a single descriptive or qualitative study.
Level VII
Evidence from the opinion of authorities and/or reports of expert committees.
Note. The level of evidence scheme is based on a studies quality in design, validity, and applicability to care. The higher the
level of the evidence, the greater the strength in the study. This level of evidence key is based on literature by: B. J., Swan, B.
A., Ladwig, G., & Tucker, S. (2008). Evidence-based nursing care guidelines: Medical-surgical interventions. (p. 7). St.
Louis, MO: Mosby Elsevier.
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Table D1.
Literature Review
Citation/
Purpose/
Search
Objectives
Engine
Used
Box et al.
(2018)
OVID

Evaluate the
effectiveness of
administering
“Bio- K+”, a
Lactobacillus
probiotic in
patients
receiving
antibiotics with
the goal of
lowering
healthcare
associated
Clostridium
difficile.

Study
population/
Sample/
Setting
-N = 1576
-Received
antibiotics and
probiotics:n =
649.
-Received
antibiotics only:
n = 927.
-Setting: 400 bed
community
hospital in La
Jolla, CA.,
March 29th 2016Sept 30th 2016.
-Inclusion:
Patients >18
years of age,
receiving >1
dosage of
antibiotics, and
had a hospital
stay >3 days.
-Exclusion: CDI
diagnosis within
3 days of
admission.

Study Design/
Methods/
Major Variables/
Instruments and
Measures
Retrospective cohort
study
-Scripps Institutional
review board
approved
-Probiotic
prescribing left to
providers discretion.
-Not randomized: all
patients on antibiotic
included in study.
Any patients who
received probiotics
were in the
intervention group.
-Demographic data
analyzed: length of
stay, number of
antibiotics used, ICU,
mortality rates, and
co-morbidity index
-Analysis performed
using ALESC
version3.0.1
2 tailed students Ttests, and fishers
exact tests.

Results/
Major Findings

Implications/
Critiques

Comments/
Themes

L
O
E

-Each cohort was
not demographically
similar (statistical
difference in ICU
stay and severity of
disease).
-11/649 patients
receiving antibiotics
and probiotics
developed CDI
-8/927 patients
receiving antibiotics
alone developed
CDI
CDI difference- not
statistically
significant (p =
0.16).

Patients in the
probiotic group
had a longer
length of stay,
higher “Charlson
co-morbidity
index”, and higher
amount of
antibiotics given.
Thus, results are
likely skewed
There was high
variability on
when the
probiotics were
initiated from the
start of
antibiotics.

Authors do not recommend
the use of probiotics due to
insufficient evidence
Prescribing of probiotics was
not a required practice, it was
at the discretion of the
provider. This may lead to
skewed results as the
physician may have
prescribing bias- higher risk
patients

IV

Did not analyze
type of antibiotic
prescribed

Flaw of study was they did
not analyze the type of
antibiotics prescribed with
each group to assess for
heterogeneity. Some
antibiotics carry a higher risk
in association to CDI rates.
Authors note their methods
of leaving prescribing
practices to the physicians is
more real-world applicable.
However, this variable allows
for high bias.

Note. LOE = level of evidence, N = total sample population, n = subset population, CDI = Clostridium difficile infection, ALESC = A Language and
Environment for Statistical Computing,
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Table D2.
Literature Review
Citation/
Purpose/
Search
Objectives
Engine Used

Carvour et al.
(2019)

Identify
predictors
that might
be
modified at
a hospital
level with
the goal of
decreasing
CDI rates.

Study
population/
Sample/
Setting
-N = 5029,
patients tested
for CDI.
-Sample:
hospitalized
adult >18 years
old.
-Setting:
University of
New Mexico
Hospital
May 1st, 2011September 21st
2016.

Study Design/
Methods/
Major Variables/
Instruments and
Measures

Results/
Major Findings

-Poorly designed case
Significant
control cohort study.
difference in age
-Retrospective chart
of diagnosis.
-EBSCO host
analysis from 2011-2016 Patients who are
used the clinical
greater than 65
identifying factor of CDI years of age =
assay test from data
higher risk (p =
warehouse.
0.08).
-Those who were tested
Diagnosis in ED
for CDI assay negative
more prevalent
or positive were
than any other
included in the review.
patient care area
-Utilized predictive
(p = 0.0001).
logistic regression
Patients on statin
modeling and
medication had
-Clients were
multivariable models
higher
chosen if
utilizing SAS version
association with
clinician
9.4.
having CDI (p =
suspected CDI
-Variables searched
.01). Probiotic
may be present. against: location of
usage in last 180
diagnosis or initial test,
days (p = .0001).
probiotic use, current
steroid use, diabetes,
current proton pump
inhibitor medication use,
and month of diagnosis
Note. LOE = level of evidence CDI = Clostridium difficile infection, N = total sample population

Implications/
Critiques

Comments/
Themes

Utilizing
retrospective data
chart analysis has
many flaws.
Analyzing previous
probiotic usage prior
to admission, these
findings are highly
biased as clients may
have initiated
probiotics due to
symptoms associated
with CDI such as
diarrhea.
Due to the
retrospective aspect
of the study, this
factor cannot be
clarified therefore is
not a clear link of a
risk of probiotic use.

Due to information
regarding when probiotics
were started and for what
purpose, stating probiotics
may be unsafe and may
cause CDI cannot be fully
inferred.
Randomization was lacking
as any patient suspected of
CDI was included in study.
-There was a high degree
of selection bias.
The study provides good
insight of possible factors
that may be related to CDI
rates, however due to the
design and quality of the
study, no true inferences
can be made.

LO
E

IV
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Table D3.
Literature Review
Citation/
Purpose/
Search
Objectives
Engine
Used
Dudzicz et
al. (2018)

Analyze the
incidence of
CDI among
immunosuppre
ssed patients
hospitalized in
the nephrology
and transplant
ward in the
period before,
during, and
after stopping
LP299v
probiotic
-Determine if
there are
benefits to
prophylactic
probiotic use
in patients
receiving
immunosuppre
ssion therapy

Study
population/
Sample/
Setting

Study Design/
Methods/
Major Variables/
Instruments and
Measures
Retrospective,
single-center study.
All patients in
ward during 12month intervention
period receiving
immunosuppressio
n and antibiotic
were given
prophylactic
probiotic- LP299v,
orally once per day
Data was
compared to 12month preintervention of no
probiotic
intervention and
12-month post
intervention period
of no probiotic.
Data analyzed
with STATISTICA
12.0PL, Chi² tests,
and an alpha 0.05

Results/
Major Findings

Implication
s/
Critiques

Comments/
Themes

LO
E

-N = 5341
After initiation of
This is the
Interesting the study
IV
-n = 24 (total
LP299v prophylaxis,
first study
was done in Poland as
patients on
incidence rate of CDI
found to
this likely would not
-CINAHL
immunosuppressiv
significantly declined- include a
be approved by IRB
e therapy and
10.3 to 1.1 per 1000
high-risk
board in United States
antibiotics over 3patients (RR 0.11; 95
population
as administration of
year period who
% CI [0.03–0.47], p =
group.
probiotics to
developed CDI).
0.0003).
n = was
immunocompromised
-12-month pre -After cessation of
above
patients is theorized to
intervention: n =
probiotic, CDI
power
be dangerous.
10
significantly increased which was
-This study may in the
-12-month during
from 1.1 to 7.7 per
20
future be considered a
intervention: n = 2
1000 hospitalized
however,
landmark study
-12-month post
patients (RR 6.93;
this is a
supporting use for
intervention: n =12
95% CI [1.58–30.47],
very small
patients who are
-Sample: Patients
p = 0.0028
sub-sample immunocompromised
in nephrology and
-Average prophylaxis
population. -H2 blockers was
transplant wards
duration was 14 ± 7
May be
noted to be used in
receiving
days.
biased due
82% of patients who
immunosuppressiv
- The cost of CDI was
to lack of
were positive for CDI
e therapy and
17.5 PLN (4.1 €) per
same size
-Included cost savings
antibiotics (any),
one patient (converted groups in
and cost needed to
age greater than 18
to USD = 4.5 dollars). pre-intrabenefit one patient.
years old
cost of prevention for
post
-Supports the use of
-Medical
one case of CDI is
interventio
probiotics and does not
University of
262.5 PLN (61.5 €)
n groups
find any adverse
Silesia in
(Converted to USD =
events related to
Katowice, Poland.
68.9 USD)
probiotic usage.
Note: LOE = level of evidence, CDI = Clostridium difficile infection, LP299V = Lactobacillus plantarum 299v, N = total sample population, n = RR =
relative risk, CI = confidence interval, PLN = Polish -Zloty- (form of currency), USD = United States dolla
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Table D4.
Literature Review
Citation/
Purpose/
Search
Objectives
Engine Used

Study
population/
Sample/
Setting

Study Design/
Methods/
Major Variables/
Instruments and
Measures

Results/
Major Findings

Implications/
Critiques

Comments/
Themes

-39 RCT
-Systematic review with
-Heterogeneity analysis for CDI
-Wide data
“Recent
studies
meta- analysis
incidence = (p = 0.79) (low risk of bias search range
clinical
analyzed.
-4 search engines utilized
- Heterogeneity analysis for adverse
1966-2017
practice
-PubMed
-N = 9,955
(PubMed, Embase,
events (p = 0.05) (moderate risk of
-Moderate bias
guidelines
-Adults and
Central, and Cochrane).
bias)
for analysis of
do not
children
-Included studies from
- CDI incidence in intervention group
adverse events
recommend
hospitalized
1966-2017
versus control: intervention group =
-Low quality of probiotic
and those in
-Two trained reviewers
1.5% (70/4525), CDI incidence in
evidence for
prophylaxis,
the
screened abstracts.
control = 4% (164/4147), RR = .40,
adverse events
even though
outpatient,
-Selection bias controlled
95% CI [0.30-0.52], NNT = 42, 95%
group
probiotics
setting who
by use of Cochrane
CI [32-58] 60% risk reduction,
- High
have the
receive
Handbook for Systematic
GRADE score = moderate.
publication bias highest
antibiotics of
Review of Interventions
-Adverse effects in intervention group
for adverse
quality
any route and -Each study scored for
versus control:
events
evidence
received
quality by GRADE criteria -Intervention: 170/1000 = 1.7% versus - Wide
among cited
probiotics of
-Statistical analysis by
control: 141/1000 = 1.4%,
population
prophylactic
any species or RevMann Software
RR= .83, 95% CI [0.71-0.97]
sample: adults
therapies.”
concentration - Reported RR with 95%
GRADE score = low
and children
-Writer
.
CI, and NNT
-Baseline risk of 0-2% not significant
included.
notes
- Setting: 13
-Analyzed heterogeneity
reduction in CDI with probiotics (p =
-Setting has a
American
countries
with funnel plot for both
0.34)
few countries
hospital’s
mostly all 1st
CDI incidence and adverse -Baseline risk of 3-5% not significant
that may be
average CDI
world
events
reduction of CDI with probiotics (p
considered not
baseline risk
countries
-Baseline risk percentages
=0.70)
1st world.
is 3%
except:
in relation to risk reduction -Baseline risk > 5% significant risk
Turkey,
rate
reduction with use of probiotics: RR =
Chile, and
.30 (risk reduction of 70%), 95% CI
Bulgaria
[0.21-0.42] , p = 0 .001
Note. LOE = level of evidence, RCT = randomized control trial, N = total sample population, CDAD = Clostridium difficile infection, RR = relative risk,
CI = confidence interval, NNT = number needed to treat
Goldenberg
et al. (2018)

To analyze
the efficacy
and safety
of
probiotics
in
preventing
Clostridiu
m difficile
in adults
and
children by
analyzing
Clostridiu
m difficile
infection
rates and
adverse
outcomes
of probiotic
usage

LOE

I
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Table D5.
Literature Review
Citation/
Purpose/
Search
Objectives
Engine
Guillemin,
et al.
(2014)
-CINAHL

Explore the
perceived
burden from a
patient’s
perspective on
the lived
experience of in
hospital
treatment of
CDI. The study
aimed to assess
the impact and
burden of CDI
from time of
initial
symptoms,
through
hospitalization
and post
discharge.

Study
population/
Sample/ Setting

Study Design/Methods/
Major Variables/
Instruments and Measures

Results/
Major Findings

Implications/
Critiques

Comments/
Themes

LOE

-N = 24
-n = 12 French
patients (9 men,
3 women).
- Age range:
41-91 years old.
-Average
hospital length
of stay 30 days.
-n = 12
-USA patients
(10 women and
2 men).
Age range: 5078 years old.
-Average length
of stay 8 days.
-All patients
had CDI within
the 14 months
of interview
-USA and
France
-Interviews
conducted
November
2011- July
2012.

-Qualitative
(phenomenological)
-Purposive and some
convenience sampling used.
(a research company found
participants but a doctor at a
single hospital also enrolled
a few of his own patients).
-Semi-structured interviews
-Open ended questions used
-4 researchers used (2 from
each country)
-Interviews conducted via 1hour phone call that was
recorded
-Interview guide was
utilized by researchers
-Data coding performed
with Atlas.ti software.
-Data saturation was
predetermined to be when
less than 5% of new
concepts were emerging
with each interview. Data
saturation began to occur at
15th patient interviewed.
-Data was grouped into
three stages: prior to
hospitalization, during
hospitalization, discharge

-Negative effects seen in
psychological and
emotional health on patient
and family
-Subsequently patients
reported change in diet and
health habits post
discharge and through time
of interview
-Negative effects on
cognitive abilities
(experienced pre and
during hospitalization)
-Negative effects on
physical health,
experienced throughout pre
diagnosis, and post
treatment
-Negative effect on sleep
seen during and post
hospitalization
-Negative effects on
professional life
experienced diagnosis,
treatment and post
treatment
-Financial burden
experienced throughout
diagnosis, treatment and
post treatment

-Interesting article
in the terms of the
emotions,
embarrassment, and
fear patients
experienced during
CDI.
-Motivating on the
precaution’s
healthcare workers
can take to prevent
this infection.
-Brings to light the
other aspects of
burden to CDI other
than increased
mortality rated and
increased health
care costs.
-Explores the
psychologic
repercussions of the
infection.
-Supports need for
further patient
education and
support during
diagnosis

-Sample bias
likely
occurred
with the
physicians
who
recruited
patients.
-No
interrater
reliability or
formal
education
for
interviewers
was stated
which may
skew the
participants
reports.
-Interview
was
conducted
over the
phone which
leaves the
patient’s
non-verbal
ques out for
examination.

VI

Note. LOE = level of evidence, CDI = Clostridium difficile infection, N = total sample population, n = sub population
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Table D6.
Literature Review
Citation/
Purpose/
Search
Objectives
Engine
Hassan et al.
Determine
(2018)
efficacy
and safety
-PubMed
of
probiotics
in adult and
pediatric
cancer
patients

Study population/
Sample/ Setting
-25 studies included
-Pooled N- 2242
-Cancer patients receiving
chemotherapy, radio
therapy or surgery whom
received probiotics as an
intervention- Outcomes
assessed: antibiotic
associated diarrhea,
gastrointestinal infections
and any adverse events.
-Setting- inpatient
-Japan, Italy, Canada,
Australia, Greece, China,
Slovakia, Brazil,
Thailand, Spain, Finland,
India, Hungary.
-1995-2018

Study Design/Methods/
Major Variables/
Instruments and Measures
-Systematic review and metaanalysis
-Focused on obtaining RCTs,
non-randomized studies and
case reports were included in
safety analysis.
- Databases searched:
Medline Embase, AMED.
-Selection- 2 reviewers 1
separate party for
discrepancies
-Cochrane risk of bias tool
used to minimalize selection
risk
-Loke Method used to assess
quality of studies
-Data analyzed by MantelHaenszel method
- 16 studies used probiotics
with >1 strain of bacteria, 11
studies include >3 strains, 18
studies included
Lactobacillus strains, 15
included Bifodobacterum
-Outcomes assessed:
antibiotic associated diarrhea,
gastrointestinal infections
and any adverse events

Results/
Major Findings

Implications/
Critiques

Comments/
Themes

LOE

-Pooled analysisreduced incidence of
AAD: OR=0 .52, 95%
CI = [0.34-0.78]
-Results concerning
severe diarrhea,
septicemia, and central
line infections had poor
confidence intervals due
to high heterogeneity
reported in studies
-Severe diarrhea: OR =
0.67, 95% CI = [0.152.98]
-Septicemia: OR = 0.39
95% CI = [0.13-1.17]
-Adverse events in
intervention group = 237
Adverse events in
control group = 314
-Author states no
conclusions of probiotic
efficacy nor safety can
be determined due to the
vast heterogeneity
between each study

-Sub group
analysis of
age, cancer
treatment type
and strain of
probiotic not
able to be
completed due
to significant
heterogenicity
-Performance
bias high 29%
-Author
reports it is
unclear if
adverse events
were recorded
with each
incidence or
per person

-No studies
from
America.
Possibly
due to high
risk patient
population
and strict
research
requiremen
ts.
-Focused
on safety
aspect on a
high-risk
population

I

Note. LOE= level of evidence, N- total sample population, RCT- randomized control trial, AAD = antibiotic associated diarrhea, OR = odds ratio, CI =
confidence interval
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Table D7.
Literature Review
Citation/
Purpose/
Search
Objectives
Engine
Used
Johnston et
al. (2012)
-PubMed

Determine
the efficacy
and safety of
probiotics
(any strain or
dose), for the
prevention
of CDAD in
adults and
children
receiving
antibiotics

Study
population/
Sample/
Setting
-N = 3,818 adult or
pediatric
patients in randomized
control trials treated
with antibiotics and
received probiotics of
any strain or dosage
that were tested for
CDI/stool analysis
-Duration of patient
follow up ranged from
1 week to 3 months
-Study’s initiation and
duration of probiotic
treatment varied
-Setting: Inpatient and
outpatient.
-Date of studies ranged
from 1989-2010
-Sample size was not
large enough to meet
power. Needed 5,676
samples, only obtained
3,818

Study Design/
Methods/
Major Variables/
Instruments and
Measures
-Systematic Review
of literature and
meta-analysis
-6 credible
databases utilized
for search
-2 independent
reviewers analyzed
studies meeting
criteria for
involvement.
- Each individual
article was assessed
for quality using
GRADE approach
- 20 RCTs were
included in analysis.
-Used relative risks
and 95% CI, used
alpha of (0.05) and
Beta of (.20) with a
relative risk
reduction of 30%
using the
DerSimoninan-Laird
Random effects
model

Results/
Major Findings

Implications/
Critiques

Comments/
Themes

LO
E

-Risk bias was low in 7 studies
and high/unclear in 13 studies
- Overall quality of evidence
moderate. Baseline risk of CDI
ranged from 0-40%
- Findings: patients receiving
probiotics showed risk reduction.
RR = 0 .34, 95% CI = [0.240.49], Chi squared = 0%, and
heterogeneity = (p = 0.79) bias
low.
- Control risk = 50 cases per
1000 persons
- Intervention group 17 cases per
1000 persons 95% CI [12-25]
-Writer notes effect size for CDI
reduction is moderate but no
statistics are given
- Studies using multiple species
probiotic versus single strain
showed relative risk reduction of
CDI however not statistically
significant
Multi-strain: RR= 0.25, 95% CI
= [0.15-.41]
Single species: RR = 0.50, 95%
CI [0.29-0.84]

-Date of literature
reviewed
included studies >
10 years old
- Low
heterogeneity
between studies is
good.
-Too small of
sample size / high
risk of type 2
error. Did not
meet power
analysis
- Overall
significance was
rated as
“moderate”
effect, no
statistical number
given.
-13 of the 20
studies data for
CDAD were
missing for 545% of patients.

-Assessed
which stain
appears to be
most
effective.
- Supported
use of
probiotics/
risk reduction
-Inadequate
sample size
-Safety
analyzed
-High
variation in
initiation of
probiotic and
follow up
length

I

-Supports use
of probiotics

Note. LOE = level of evidence, CDAD = Clostridium difficile-associated diarrhea, CDI = Clostridium difficile infection, RCT = randomized control
trials, CI = confidence interval, RR = relative risk
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Table D8.
Literature Review
Citation/
Purpose/
Search
Objectives
Engine
Used
Kamdeu
Fansi, et al.
(2012)

-PubMed

Perform a costbenefit analysis
utilizing previous
study findings
to estimate the
direct medical
costs that might
result from the
use of a Bio K+
(Lactobacillus
containing
probiotic),
formula in two
different doses to
reduce the risk of
AAD and CDI in
hospitalized
patients on
antibiotics
translated into
costs based in
North American
healthcare

Study
population/
Sample/
Setting
Based on
study analyzed
for cost
analysisN = 255
-Placebo: n =
84, cohort 1
(one capsule
dosage): n =
85, cohort 2
(two capsule
dosage): n =
86
- Study data
obtained from
Gao et al
(2010) RCT
performed in
China in
2008-2009.
Inclusion> 18
years of age,
hospitalized
>3 days <14
days.

Study Design/
Methods/
Major Variables/
Instruments and
Measures
-Probiotic administered
within 36 hours of antibiotic
-Cost were determined
based on the 2009 United
states dollar, using the
Consumer Price Index.
-Only direct costs
determined- no adjusts for
quality of life
-Hospital costs determined
by the median cost of
hospitalization in relation to
diagnosis of CDI which was
obtained from a USA study
in 2009
-Authors utilize a decision
tree to formulate 5
assumption models.
-Utilized Crystal Ball
software for all the analysis
data

Results/
Major Findings

Implications/
Critiques

Comments/
Themes

LOE

Study found decreased
incidence of CDI with
probiotics versus placebo:
Placebo= 23.8%, Cohort
1= 9.4%, Cohort 2 = 1.2%
-Cost of CDI related
hospitalization per patient,
per day= 1,424.16
- Findings supported cost
effectiveness of probiotics:
-Due to reduced risk
reduction and reduced
incidence of CDI, by
implementing dosage of 1
probiotic per day for all
patients at risk, results in a
savings of 981 dollars per
patient.
-Implementing dosage of 2
probiotics per day results
in savings of 833/patient.
-For a hospital comparable
to the one in the Gao
study, this results in
1.68million dollars savings
for an institution

-Very
thorough cost
analysis.
Provided
numerous
scenarios/ass
umptions
-Strong
quality study.
-The Gao
study which
was
analyzed, has
higher rates
of CDI
baseline than
most
American
hospitals do.

Must keep in
mind, these
figures are
based off of
values from one
study.
However, it is
beneficial to see
the cost savings
that occurs
when few cases
of CDI are
prevented.

I

Note. LOE = level of evidence, AAD = antibiotic associated diarrhea, CDI = Clostridium difficile, N = total sample population, n = sub-sample
population, RCT = randomized control trial.
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Table D9.
Literature Review
Citation/
Purpose/
Search
Objectives
Engine Used

KujawaSzewieczek et
al. (2015)

Study
population/
Sample/
Setting

Study Design/
Methods/
Major Variables/
Instruments and
Measures

Results/
Major Findings

Implications/
Critiques

Comments/
Themes

LOE

Retrospectively
analyze CDI
rates among
patients whom
are hospitalized
and receiving
antibiotics
before the start
of routine
administration
of LP299V to
all patient
receiving
antibiotics as
hospital
protocol for
patients in the
nephrology and
transplantation
wards.

-N = 3533
-Retrospective quasi-Decreased
-No mention if
-In the intervention
IV
-CDI
experimental single
incidence of CDI
control versus
time frame, less
preintervention: n center study (casepost intervention
intervention
antibiotics were
= 21
control)
from 1.21% to
group were
prescribed. Thus,
-CDI post
-In the period between
0.11%, p = 0.0001
similarresults may be skewed
-PubMed
intervention: n = 2 2012-2013 the unit’s
-Total analysis of
(heterogeneity)
due to less high-risk
-Setting:
routine was to
both groups
no p values
antibiotics being used.
nephrology and
administer probiotics of identified urinary
provided.
-PPI use was noted in
transplantation
any variation to reduce
tract infection was
-Demographics
86% of patients who
ward at a medical incidence of CDI
the main diagnosis
of total
had CDI. In the
university in
-2013-2014 LP299V
and reason for
population not
intervention group less
Silesia, Poland.
was the only probiotic
treatment with
provided.
patients took PPIs
-Data analyzed for administered
antibiotics which
Study methods
-This patient
2 years
concurrently with the
led to CDI
not clear
population is
-October 2012start of any antibiotic
-Fluoroquinolones
Retrospective,
considered a higher
October 2013
-CDI diagnosis made
34.8% and
but unclear if
risk patient population;
(prior to hospital
by 2 step
carbapenemsstaff was blinded these findings may
protocol
immunoassays. Any
34.8% had the
or knew study
support that probiotics
initiation)
patient with diarrhea
highest association was being
may be safe in
-November 2013- was tested.
with CDI.
performed
immunocompromised
November 2014,
-Statistical analysis
-Total amount of patients
data analyzed
performed by
patients who had
after hospital
STATISTICA 7.0
CDI was lowprotocol initiated
-alpha set as: 0 .05
24/3533
to start LP299V
-Power for study
with all
was not specified
antibiotics.
Note. LOE = level of evidence, CDI = Clostridium difficile infection, LP299V = Lactobacillus plantarum strain 229v, N = total sample population, n =
total sub-sample population
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Table D10.
Literature Review
Citation/
Purpose/
Search
Objectives
Engine
Used

Study
population/
Sample/
Setting

Study Design/
Results/
Implications/
Comments/
Methods/
Major Findings
Critiques
Themes
Major Variables/
Instruments and
Measures
Lau &
Analyze the
26 RCTs
-Systematic Review and
-No publication bias - Flaw is that the
- Overall thorough
Chambincidence of
N = 7,957
Meta-Analysis
present: Eggers test
review includes
meta-analysis
erlain
CDI in
Received
-Comprehensive Meta(p = 0.748)
seven studies that
- Many of the studies
(2016).
randomized
probiotics: n =
Analysis software
-No significant
were greater than 10 included in the
clinical trials
4,124,
version 3.
heterogeneity
years old.
analysis do not note
PubMed
which assess
No intervention: n
-Cochrane’s Q and I²
between trails (p =
- Limitations in
the side effects of
the use of
= 3,833
to assess study
0.751).
differences in strain, probiotics. However,
probiotics for -Inclusion: RCT
heterogeneity
-Probiotic group had dosage, and
four studies did
adult and
comparing the use
-Two tailed T-test used
significant
duration of
report no significant
pediatric
of any strain
for data sets.
decreased risk in
probiotics used.
difference in side
patients in
probiotic, articles
-Sub-group analysis
developing CDI:
-Heterogeneity
effects from probiotic
the inpatient
in English,
performed on type of
RR= 0.63, 95% CI = present in patient
group to placebo.
and
probiotics
probiotic used, age, and
[0.294-0.531], p =
age, co-morbidities,
- Supports the use of
outpatient
instituted within 3
patient setting (inpatient
0.001
and healthcare
probiotics
setting who
days of antibiotic
vs outpatient)
-Hospitalized
setting.
-Author addresses
are receiving
start, and
-Funnel plot utilized to
patients were likely
-Wide sample
there are a few case
antibiotics.
continued for the
rule out selection bias.
to benefit from
range- inpatient and reports noting sepsis
entire duration of
-Search engines used:
probiotic use
outpatient included
believed to be related
the antibiotic
PubMed, Cochrane, and
compared to
as well as adults
to probiotic use.
treatment.
Google Scholar
outpatients
versus children.
They discern this
Exclusion: most
-Diagnosis of CDI made -Inpatient: (RR =
- no mention on
evidence as being
studies excluded
by presence of diarrhea
0.390, 95% CI
how studies were
inconsistent, and not
patients that were
and positive stool
[0.283-0.538], p =
measured for quality statistically
severely
culture
0.001) -Outpatients
or how many
significant.
immunocompromis -Measured CDI rates,
(RR = 0.306, 95%
reviewers were
ed, and who had
patient length of stay,
CI [0.013-7.470], p
included.
gastrointestinal
patient age, and hospital
= 0.468)
surgery.
versus outpatient setting
Note. LOE = level of evidence, CDI = Clostridium difficile infection, RCT = randomized control trial, N = total population sample, n = sub-population
sample, p = measure of statistical significance, RR= relative risk, CI= confidence interval

LOE

I
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Table D11.
Literature Review
Citation/ Purpose/
Search
Objectives
Engine
Leal
Performed a
et al.
cost(2016)
effectiveness
analysis to
CINAHL evaluate the
risk of CDI
and the costs
of receiving
oral
probiotics
versus no
probiotics
over the
course of 30
days.

Study
population/
Sample/Setting
-23 RCT studies
examined and
published by
the Cochrane
Review
-Studies
included in the
systematic
review: Adult
inpatients
receiving
antibiotics
regardless of
route of
administration
and received an
intervention of
probiotic of any
species or
concentration.
- Studies
utilized;
continued
probiotics for at
least 5 days
post antibiotic
completion.

Study Design/Methods/
Major Variables/
Instruments and Measures
-Systematic review
-Data from Cochrane
review was utilized to form
a cost analysis.
-Relative risk rates of CDI
and increased length of
hospital stay was derived
from systematic reviews
-Length of treatment for
CDI, length of probiotics,
cost for stool analysis,
special room cleaning,
additional supply cost, and
contact precaution costs all
included in analysis and
obtained from Alberta
Health Services records
(public funded healthcare
system).
- Cost per day of contact
precautions was used from
a study performed in 2012.
-Utilized 1-way sensitivity
analysis for assessing cost
savings per relative risk
rates.
- Did not directly assess
quality of life indicators
into cost versus savings

Results/
Major Findings

-Reduced risk of CDI in intervention
group 5.05% versus 2%
- Cost of probiotics per patient if
administered during course of antibiotic
therapy and 5 days post completion = 24
dollars.
- Cost per patient treated for CDI if
relative risk is 5% in intervention group
= 327 dollars versus non-intervention
group = 845 dollars. Cost savings of 518
dollars per patient.
-Cost savings per patient if relative risk
is 1% (low) is 73 dollars per patient
treated.
- Cost savings per patient if relative risk
is 25% (high) is 3,098 dollars per treated
patient
- Writer expresses the high likelihood of
increased patient satisfaction/ quality of
life with reduced risk of CDI with the
probiotic intervention due to reduced
risk for lengthened hospital stay, the
emotions related to being in isolation,
and the physical complications that arise
from CDI (p.1082).
-Theoretically for a hospital with
380,000 admissions the cost for
probiotics would be 2.2 million dollars
but may result in a 44-million-dollar
savings (p. 1085).
Note. LOE = level of evidence, CDI = Clostridium difficile, RCT = randomized control tria

Implications/
Critiques
-On average
patients with
CDI spend 1-3
weeks longer
in the hospital
(p.1079).
- Funding
provided by
Alberta Sepsis
Networks and
National
Collaborating
Centre for
Infectious
Disease, and
Baxter.
- American
hospital
average risk
for CDI is
about 3%
- Flaws: No pvalues, effect
sizes, nor
confidence
intervals stated
in article.

Comment
s/
Themes
-Cost
savings
-CDI
reduction
Discusses
possible
quality of
life
implicatio
ns for use
of
probiotics.
Sampling
bias
unclear
Statistical
significan
ce not
provided

L
O
E
I
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Table D12.
Literature Review
Citation/ Purpose/
Search
Objectives
Engine
Lewis et
Evaluate the
al.
outcome of a
(2017)
hospital wide
PubMed
initiative to
decrease
proton pump
inhibitor
prescribing
and increase
prescribing
and
administration
of Florajen- a
multi-strain
Lactobacillus
containing
probiotic with
an analysis
goal of
determining
the impact on
hospital
acquired
Clostridium
difficile rates.

Study
population/
Sample/ Setting
-N = 43,206
-Cohort one: n =
21,166
-Cohort two: n =
22040
-Cohort/phase
one:
July 1st 2013June 30th 2014
-Cohort two:
July 1st 2014June 30th 2015
-Exclusion- Age
less than 18 and
pregnancy,
patients with
central venous
catheter lines,
immunosuppresse
d
patients, intensive
care unit patients.
-Setting: Johnson
City Medical
Center (488 bed
institution)

Study Design/Methods/
Results/
Implications/
Comments/
Variables/Instruments and
Major Findings
Critiques
Themes
Measures
-Single center retrospective
-Statistically
-Flaw is that the
The protocol
cohort study
significantly decreases
study does not
for
All patients admitted to
from cohort one to
include
administration
hospital included in study.
cohort two: PPI usagerandomization and
of the
Standard infection control
677 to 581, (p = 0.0002). is retrospective
Lactobacillus
measures maintained for all
Health care associated
-Complete
probiotic
patients.
CDI rates (number of
effectiveness of
contained safe
-Methods: during phase one, CDI rates per 1000
probiotics cannot
handling
physicians were educated
patient days) 0 .49 to
be truly determined instructions to
on risks of PPI prescribing
0.39 (p = 0.04). This
due to additional
prevent
in relation to increased CDI
represents a relative risk
variable of reduced probiotic
rates. -A probiotic bundle
reduction of 20%
prescribing of PPIs related
was included in order sets
-Probiotic usage
- Overall, good
infection:
for all patients receiving
increased significantly
quality of a small
Administered in
antibiotics
from cohort one to
institutional
capsule route. If
Florajen was ordered as a
cohort two: 97 to 223 (p
change Adding
patient has a
once per day dosage.
= 0.0006.)
probiotics to an
nasogastric
-Hospital associated CDI
-Cost savings: the
antibiotic
tube, the
was defined as diagnosis
average additional costs
prescribing order
probiotic
after 3 days since admission associated with hospital
set is a good
cannot be
and diagnosis was made
acquired CDI for this
method to increase administered.
using a polymerase chain
institution is 11,000
usage. This also
Nurse
reaction test Cohort
dollars per patient. A
allows prescriber
administers
comparison tests were made reduction in 12 cases
autonomy as they
medication
using a Mann-Whitney test.
over the year (which was can elect to not use wearing gloves
To analyze a cohort’s
seen in this study),
the probiotics as
and performs
impact on CDI rates a
results in a savings to the well
hand hygiene
Fischer’s exact test with an
institution of 130,000
after
alpha of 0.05 was used.
dollars per year.
administration.
Note. LOE = level of evidence, N = total sample population, n = sub-sample population, PPI = proton pump inhibitor, CDI = Clostridium difficile
infection, p = measure of statistical significance

L
O
E
IV
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Table D13.
Literature Review
Citation/ Purpose/
Search
Objectives
Engine
Used
Li et al.
(2018)
CINAHL

Cost analysis to
assess the benefits
financially for the
institution and also
assessing quality of
life via length of
hospital stay in
relation to the use of
prophylactic
probiotics for the
prevention of
Clostridium difficile
in adolescents and
children.

Study
population/
Sample/
Setting
- Four randomized
control trials
analyzed with
measured outcomes
being incidence of
CDI and direct
medical costs
related to treatment
of the incidences of
CDI.
-Hospitalized
patients less than 18
years of age
receiving antibiotics
intravenously or
orally and probiotics
-The 4 studies were
not described in
depth, no setting
was provided.

Study Design/
Methods/
Major Variables/
Instruments and
Measures
-Systematic review
and meta-analysis
-Studies searched via
online sources:
PubMed, EMBASE,
and Cochrane
Library.
- 2 independent
reviewers assessed
literature. Cochrane
handbook was used
to prevent selection
bias
- Cost analysis was
based off of United
States hospital costs.
- Univariate
sensitivity analysis
was used along with
a decision tree model
to analyze data

Results/
Major Findings

Implications/
Critiques

Comments/
Themes

LOE

- Oral probiotics lowered
risk of CDI 4.6% to
0.45%. No confidence
interval or p value given.
- Cost of probiotics per
day averaged 2.83
dollars.
- For institution with the
probiotic strategy total
cost per patient treated
for was 16,668.70
dollars compared to
20,355 dollars per
patient treated in the
non- intervention
hospital due to risk
reduction
- Cost savings of 3,686
dollars per patient
treated.
- No data on selection
bias/ heterogeneity of
studies was provided

-Small number
or studies
analyzed (4)
-Vague
information on
the 4 studies
analyzed
- Information
posted in
medical
journal, likely
there was page
limit
constraints.
- Statistical
process not
well explained.
- Statistical
data not
supported with
confidence
levels or p
values.

-Use of
probiotics
appear to reduce
incidence of
CDI and have
cost savings for
a hospital

I

Overall, poor
quality
systematic
review due to
lack of detail
and

Note. LOE = level of evidence, CDI = Clostridium difficile infection
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Table D14.
Literature Review
Citation/
Purpose/
Search
Objectives
Engine
Used
Maziade
Determine the
et al.
effect of adding a
(2013)
probiotic called
-PubMed
Bio-K+ (Lacto
acidophilus and L.
casei) to an
existing
Clostridium
difficile standard
precaution measure
protocol (proper
handwashing,
modified contact
precautions for
current patients
with CDI and
antibiotic
stewardship), in
patients receiving
any antibiotics.
The primary
outcome to be
measured was CDI
rate/occurrence
and secondary
measurement of
severity of CDI
symptoms

Population/
Sample/
Setting

Study Design/Methods/
Major Variables/
Instruments and Measures

Results/
Major Findings

-N- 31,832
-Phase one: n =
1,580
-Phase two and
three: n = 4,968
-Phase 4: n =
25,284
-Phase one:
August 2003January 2004
-Phase two:
February and
March 2004
-Phase three: May
2004-August
2005
-Setting:
community
hospital in
Quebec, Canada.
-Inclusion
criteria: age >18
years old
-No exclusion
criteria disclosed

-Open prospective quasiexperimental cohort study
-Methods- Probiotic
administered within 2-12
hours of any antibiotic.
Probiotic continued for 30
days or until antibiotic
completion.
-Consisted of four phases:
1- Standard precautions
2. Implementation of liquid
probiotic for all patients on
antibiotics
3. Hospital relocated/new
built hospital
4. Data comparison with
regional hospitals near
Quebec
-Instruments- SPSS data
analysis
Measures: level of
significance, alpha- 0.05
Incidence rates between
phases compared with 2sided chi-square tests and
student’s T- tests

-Phase 1: Mean of 18.4
cases per 1000.
5.1 severe cases per 1000
people.
-Phase 2: Severe cases of
CDI decreased from 5.1
cases per 1000 to 1.3 cases
per 1000, (p = 0.03).
-Phase 3: Cases of CDI
dropped from Phase one
mean of 18.4/1000 to
3.8/1000. (p = 0.003).
-Severe cases decreased
from 5.1/1000 patient to
0.21/1000 patients (p =
0.001)
When comparing phase 1
with phase 2 and 3
combined, (preintervention with post
intervention), rates of CDI
decreased 73% (p = 0.001)
Severe cases of CDI rates
decreased 27.5% (p =
0.001)
-No adverse events found

Implications/
Critiques

Comments/
Themes

-In phase three, -The authors
the hospital renote, no
located and
approval was
double rooms
needed from
were less
the ethical
available.
review board.
-Patient
This is a
demographics
common
were not
theme in
presented for
studies
each phase
performed
therefore
outside of the
similarity
USA.
between the
-Unique in no
two groups
exclusion
cannot be
criteriadetermined.
allowed high
- apache scores
risk patients
had no
to be
significant
involved
difference
central
between the
venous lines,
two groups.
intensive care
-Study was of
unit patients,
good quality
cardiac valve
Study
replacement
supported the
use of
probiotics
Note. LOE = level of evidence, CDI = Clostridium difficile infection, N = total sample population, n = subset population, p = measure of statistical
significance

LO
E

IV
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Table D15.
Literature Review
Citation/ Purpose/
Search
Objectives
Engine
Used
Pattani
et al.
(2013)

Systematic
review and metaanalysis of
evidence to
determine the
efficacy of
probiotic
administration
concurrently
with antibiotic
administration in
adult
hospitalized
patients to
prevent CDI
and/or AAD,
incidence and in
return decrease
mortality and
decrease health
care costs.

Study
population/
Sample/
Setting

Study Design/
Methods/
Major Variables/
Instruments and
Measures

Results/
Major Findings

Implications/
Critiques

-16 studies included
focusing on hospitalized
adults receiving
antibiotics and probiotics
containing one or more of
the following:
Lactobacillus,
Saccharomyces boulardii
and or Enterococcus with
the end point assessing
CDI, and/or AAD rates,
-Inclusion: studies in
English, designed as
RCTs.
-Exclusion: probiotics
used for reoccurring CDI
treatment of H.pylori.
-Only 5/16 studies were
multicenter
- Studies were conducted
in USA, UK, China,
Canada, Italy, Norway,
Turkey, and Switzerland.
-Mean ages: 33-79.9

-Systematic Review & MetaAnalysis
Search engines used: Medline,
Embase, Cochrane.
-3 reviewers analyzed each
article to limit inclusion bias
-Each article was reviewed by
2 independent reviewers using
the global quality rating scale
(good, fair, or poor).
Disagreement on an article
was resolved by 3rd reviewer.
-Data synthesis tool used for
meta-analysis: RevMan 5.0 a
Cochrane collaboration tool.
- RR, RD, NNT, & 95% CI,
calculated by DerSimonian
Laird Method.
-Clinical heterogeneity was
assessed for population type,
probiotic type, and quality of
study.
-Funnel plot used to assess for
publication bias.

-Rates of CDI = 3%
or 18/572
intervention and
55/527 in placebo
yielding a RR =
0.37, 95% CI [0.220.61], RD = 0.07,
95% CI [0.11-.0.02].
NNT 14, 95% CI [950]
-Meta analysis of
type of probiotic in
relation to reduction
of rates of AAD and
CDI all showed
reduction. However,
only the combined
Lactobacillus
probiotics showed a
significant reduction
in CDI & AAD.
-No effect size noted

-Moderate
degree of
publication
bias present
-There may
be differences
in styles of
nursing
practice to
prevent CDI
or antibiotic
prescribing
practices may
differ between
the various
studies
leading to
different/skew
ed results in
each
individual
study.

Comments/
Themes

-Although
article sounds
promising, the
NNT in
-PubMed
relation to
reduction of
CDI, (4, 95%
CI [9-50]), is a
large CI this is
concerning as
cost vs benefit
may not be
there if NNT
is closer to 50.
-Probiotics
containing
Lactobacillus
seem to be the
most
efficacious
choice
-Article
supports the
use of
probiotics to
reduce risk of
CDI and AAD
Note. LOE = level of evidence CDI = Clostridium difficile infection, AAD = antibiotic associated diarrhea, RCT = randomized control trials, H. pylori =
Helicobacter pylori, RR = relative risk, RD = risk difference, NNT = number needed to treat, CI = confidence interval

LOE

I
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Table D16.
Literature Review
Citation/ Purpose/
Search
Objectives
Engine
Used
Redman
Perform a
et al.
systematic
(2014)
review
and metaPubMed
analysis of
literature
to collect
data
regarding
the safety
and
efficacy of
probiotic
usage in
people
with
cancer

Study
Population,
Sample/ Setting

Study Design/Methods/
Major Variables/Instruments and
Measures

- N = 1530
-Control: n = 756
-Treatment: n =
group- 774
- Adult cancer
patients
-Inclusion
criteria- enrolled
in RCT,
diagnosed with
cancer, receiving
probiotics, and
studies with
secondary
analysis of
safety.
-Setting: RCT in
Finland, Brazil,
India, Thailand,
Hungary, Italy,
China, Japan,
Canada, and
Spain
-17 studies
analyzed safety
-11 studies
analyzed
efficacy.

-Systematic Review with Metaanalysis
Data collected from 17 different
search engines. A 40-step search
strategy was performed using
Medline, Embase, and Amed
Data collection took place from
2010- 2012.
-2 independent reviewers for
study selection, 1 separate
review used for disputes.
Studies were reviewed utilizing
Cochrane collaboration risk for
bias assessment tool
-Data analyzed using Rev Man
5.2 system.
-Variables- decreased incidence
of diarrhea utilizing the common
toxicity criteria for analyzing
degree and severity of diarrhea
and adverse outcomes

Results/
Major Findings

Implications/
Critiques

Comment
Themes

-Efficacy: probiotics may be
-Study does
-Article seems to
beneficial in reducing frequency not provide in support use of
of diarrhea: OR = 0.32, 95% CI
depth pooled
probiotics and
[0.13-0.79] p = 0 .01
demographics infers that cancer
-Data to support probiotics may
of population. patients are
reduce frequency of bowel
-Case reports immunocompro
movements appears promising,
were included mised and likely
however only two studies were
in statistics
to have the
included in this analysis and bias for safety
highest risk of
was high in studies. Therefore,
-Effect size
adverse events,
full conclusions cannot be drawn not noted for
yet appear to not
(mean bowel movements per day statistic
have a significant
decreased by 9.6 movements,
results
difference in
95% CI [10.45- 8.75], p =
-Inclusion
adverse events.
0.00001
and exclusion
-Safety: pooled adverse events
criteria
-The authors do
in probiotics = 103 versus
explanation
describe the case
placebo =145
was brief
studies that note
-No statistical analysis for
- No
connection to
significance noted for adverse
statistical
probiotics to
events.
evidence to
severe adverse
-Author note: due to the
determine if
events. In some
Clinical heterogeneity was
significant heterogeneity of
adverse
cases, the
assessed for selection criteria,
treatment options and variation
events are
adverse events
performance, detection bias,
of standard of cares and
significant
are proven to not
attrition bias, and reporting bias. numerous variables, determining
be related to
Bias detected by I² > 50%
which adverse effects are related
probiotic usage.
to probiotic consumption is
fairly impossible
Note. LOE = level of evidence, RCT = randomized control trial, N = total sample population, n = sub sample population, OR = odds ratio, CI =
confidence interval, p = measure of statistical significanc

LO
E

I
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Table D17
Literature Review
Citation/Se Purpose/
arch
Objectives
Engine
Used

Sadanand
et al.
(2019)

Evaluate the safety of
Lactobacillus
rhamnosus probiotic
as a treatment method
in the pediatric patient
population who are
experiencing graft
versus host disease
(GVHD) and/or who
have recently
undergone HSCT
many of whom have
CDI or other GI
ailments. The aim
specifically was to
assess for probiotic
associated bacteremia.

Study
population/
Sample/
Setting

N = 15
Median age = 7
60% of
population had
an
unmatched/unrel
ated donor.
Pediatric
allogenic HSCT
recipients

Study Design/
Methods/
Major
Variables/
Instruments and
Measures
-Single-center
retrospective
study

Results/
Major Findings

Implications/
Critiques

Comments/
Themes

-5/15 patients
-No statistical
Study evaluates
experienced blood data provided.
safety of
stream infections
-Large variation
probiotics in a
within the first
in the population high risk-Probiotic doses 100 days of
characteristics
immune
PubMed
varied from one transplant. None
-No rigor in
suppressed
capsule or
of these cases
study due to
group.
packet daily to
occurred while a
prospective
This study does
two packets
patient was on the nature.
not analyze the
four times
Lactobacillus
- Low power as
efficacy of
daily.
rhamnoses
only had 15
probiotics as a
2011-2016
-Primary
probiotic. None of patients
prophylactic
analysis of
the 5 cases of
-Fair study. Most method.
bacteremia
bacteremia were
shows the safety
Large variation
-Secondary
related to the
of probiotics in a in the dosage of
analysis of what Lactobacillus
very high-risk
probiotics
immunosuppres species.
population.
administered.
sive medicine
70% of the
the patients are
patients had CDI
on. occurrence
or GI GVHD by
rates of GVHD
day 100 and were
and presence of subsequentially
CDI
started on
probiotics after
symptoms started
Note. LOE = level of evidence, GVHD = graft versus host disease, HSCT = hemopoietic stem cell transplant, CDI = Clostridium difficile

LOE

IV
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Table D18.
Literature Review
Citation/ Purpose/
Search
Objectives
Engine
Used
Selinger
To determine if a
et al.
probiotic
(2013)
containing:
CINAHL Bifidobacterium
breve,
Bifidobacterium
longum,
Bifidobacterium
infantis,
Lactobacillus
acidophilus,
Lactobacillus
plantarum,
Lactobacillus
paracasei,
Lactobacillus
delbrueckii
subsp.
bulgaricus,
Streptococcus
thermophilus,
reduces the risk
of CDI and
antibiotic
associated
diarrhea as well
as analyze
adverse events

Study Population,
Sample/ Setting

Study Design/Methods/
Major Variables/Instruments and
Measures

Results/
Major Findings

Implications/
Critiques

Comment
Themes

L
O
E

-N = 122
-Placebo: n = 61
-Intervention: n = 61
-Adult hospitalized
patients receiving
systemic antibiotics
-Exclusion criteria:
severe nausea and
vomiting, no oral
access, ICU
admission, had
diarrhea prior to
study initiation, acute
pancreatitis, previous
use of probiotics 1
week before study
initiation, severely
immunocompromised
, (not specified).
-Four hospitals:
Albert Edward
Infirmary, North
Bristol, Hull Royal
Infirmary, and
Weston General
Hospital
-April 2010-Feb
2012.

-RCT (stated in article) reviewer feels
it is Quasi- experimental due to
sampling technique
-Double Blind
-Stratified cluster sampling used
-Patients were assessed for eligibility,
if consent approved, were
administered probiotic or placebo
within 48 hours of first antibiotic.
-Probiotic and placebo administered
twice per day for the duration of
antibiotic treatment and 7 days after.
-Patient diary: reported if medication
was taken, symptoms, number of
stools, and stool characteristics.
-Daily Bristol stool charts. If stool was
categorized as type 6 or 7 twice in one
day, a stool sample was sent for CDI
testing.
-CDI testing performed using Premier
Toxin A+B at Hull and Bristol site.
Quick Check complete test was used
at Weston and Wigan sites
-

-No determination
could be made on
reduction of CDI
rates as neither
group had an
incidence of CDI.
-Significant
reduction of AAD
was noted (p =
0.006)
-There was no
significant
difference in length
of hospital stay.
- Adverse side
effects were not
significant between
the control and
interventional
group (p = 0.63)
In fact, the placebo
group had higher
rate of side effects
8.9% vs 6.8%
supporting the
minimal risk/side
effects of
probiotics

-Low N, Power
analysis for 90%,
5% LOS, N
needed to be >389
-Poor retention
during study:
initial enrollmentN = 231. end
point- N = 122.
- Poor retention
-Study used two
different
instruments
depending on site
to test stool
samples for CDI.
Imposes high risk
of error
-The “average
risk” and
“severely
immunocompromi
sed patient not
defined.
- Study funded by
pharmaceutical
company

Cannot
determine
if CDI is
reduced as
no cases
were
noted.

III

-Poor
sampling
-Does
state that
adverse
effects
were not
significant
vs placebo

Note. LOE = level of evidence, CDI = Clostridium difficile infection, N = total sample population, ICU = intensive care unit, RCT = randomized control
trial, AAD = antibiotic associated diarrhea
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Table D19.
Literature Review
Citation/ Purpose/
Engine
Objectives
Shen et
al.
(2017)
PubMed

-Primary
purpose:
review RCT
studies and
analyze if the
use of
probiotics
reduces
incidence of
CDI.
Secondary
purpose was
to determine
if there was a
correlation to
type of
probiotic
administered,
dosing of
probiotics,
timing of
initiation,
duration of
treatment and
quality of
studies
analyzed.

Study Population,
Sample/ Setting

Study
Design/Methods/

Results/
Major Findings

Implications/
Critiques

Comment
Themes

-19 RCTs analyzed
-Total sample: N = 6,261
-Probiotic: n = 3,277
-Placebo: n = 2,984
-Mean age: 68
-Inclusion criteria:
hospitalized patients, age 18
years or older on antibiotics
IV or oral, receiving
probiotics as a primary
prevention method.
-Excluded patients:
pregnant, neutropenia, HIV,
malignant cancer, transplant
patients receiving
immunosuppression, and
preexisting GI disorders.
-Probiotics used in studies=
12 formulations all
containing Lactobacillus,
Saccharomyces,
Bifidobacterium, &
Streptococcus either alone
or in combination.
-Studies conducted in 8
countries: USA, UK,
Turkey, Canada, Norway,
Italy, China, & Germany.

-Systematic review
& meta- analysis
-Search engines:
Medline, Cochrane
Library, Ovid, and
ProQuest.
-2 reviewers
-Disagreements
settled by 3rd
reviewer.
- Bias controlled by
use of Cochrane
Handbook for
Systematic Review
or Interventions
-Quality of studies
analyzed using
standardized
GRADE system
- Publication bias
was assessed by
use of funnel plot
and Egger’s
regression
- Meta-regression
performed by
STATA program

-No significant heterogeneity across
the 19 studies (p = 0.56)
-Meta- analysis supports probiotic to
prevent CDI vs placebo or no
intervention
Risk of CDI in control group: 0-40%
Risk of CDI in intervention group: 011%
RR= 0.42, 95% CI [ 0.30-0.57] p =
0.001
-NNT= 43, 95% CI [36-58]
- Probiotic initiation: more effective
if started within 2 days of antibiotic
administration: RR = 0.32, 95% CI
[0.22-.48] versus greater than 2 days
from antibiotic start time: RR = 0.70,
95% CI [0.40-1.23]
- No significant difference in
probiotic formulation
effectiveness (p = 0.34)
-Writer does argue use of
Lactobacillus due to heavily studied
formula
-Analysis of adverse effects from
placebo to intervention not
statistically different (p = 0.35)
-Quality of evidence measured by
GRADE system = high quality
-No effect size noted

-Supports use
of probiotics
as primary
prevention of
CDI, most
effective if
started within
2 days of
antibiotic
initiation.
-Writer
theoretically
notes: if a
hospital’s
baseline CDI
rate is 1.5%7.4% the
research
suggests 1 case
of CDI would
be prevented
by every 23144 patients on
probiotics.

-No
financial
funding
conflictions
-Credible
researchers
-Very
strong
article

L
O
E
I

Note. LOE = level of evidence, CDI = Clostridium difficile, RCTs = randomized control trials, USA = United States of America, UK = United Kingdom, IV =
intravenous, HIV = human immunodeficiency virus, GI = gastrointestinal, RR = relative risk, CI = confidence interval, NNT = number needed to treat, p = measure of
statistical significant
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Table E1.
Theme Matrix
Item

Box et al.
(2018)
Carvour et al.
(2019)
Dudzicz et al.
(2018)
Goldenberg et
al. (2018)
Guillemin et
al. (2014)
Hassan et al.
(2018)
Johnston et al.
(2012)
Kamdeu Fansi
et al. (2012)
KujawaSzewieczek et
al.
(2015)
Lau et al.
(2016)

Methods/backgrounds
Heterogeneity/Selection
Excluded
bias/Poor methods of
high risk
sampling
patients
Y

NS

Interventional Methodology
Lactobacillus
Timing of
containing
probiotic
probiotic
effects CDI
reduction
Y
NS

Y

NS

NS

NS

N

NS

NS

Y

N

Y

Y

Y

Y

NS

N-rates of CDI
Y-Safety
Y

NS

Y

NS

Y

NS

Y,

N/A

N/A

N/A

N/A

N/A

N/A

Y

N

NS

NS

N/A

Y

Y

N

NS

Y

NS

Y

NS

Y

Y

NS

Y

Y

Y

Y

NS

Y

N

Y

Y

Y

NS

Y

Y

Y

Y

NS

Y

NS

Y

Decrease
in CDI
rates

Findings
Cost
effective

Notes side
effects of
probiotic

N

NS

NS
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Table E1. (continued)
Theme Matrix
Item
Heterogeneity/Selection
bias/Poor methods of
sampling

Methods/backgrounds
Excluded
Lactobacillus
high risk
containing
patients
probiotic

Leal et al.
Y
NS
(2016)
Lewis et al.
Y
Y
(2017)
Li et al.
Y
NS
(2018)
Mazaide et al. Y
N
(2013)
Pattani et al.
Y
Y
(2013)
Reman et al.
Y
N
(2014)
Sadanand et
Y
N
al. (2019)
Selinger et al. Y
Y
(2013)
Shen et al.
N
Y
(2017)
Note. N= no, Y = yes, NA = not applicable NS = not specified

Y

Interventional Methodology
Timing of
Decrease in
probiotic
CDI rates
effects CDI
reduction
NS
Y

Findings
Cost
Notes side
effective
effects of
probiotic
Y

NS

Y

Y

Y

Y

NS

Y

NS

Y

Y

NS

Y

Y

Y

NS

Y

Y

NS

Y

NS

NS

Y

NS

NS

NS

Y

Y

NS

NS

NS

Y

Y

NS

NS

N

NS

Y

Y

Y

Y

NS
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Table F1.
Concept Analysis Process Elements
Identified
Concept of
Interest
Probiotic

Theoretical
Definition

Operational
Definition

Antecedents

Consequences

Type of Research Design

None
Stated

-Lactobacillus
containing probiotic
administered within
three days of
antibiotic start.
-Continued for the
duration of antibiotic
treatment

-Patients 18 years
or older,
hospitalized,
receiving
antibiotics.

-12/16 studies report
reduced incidence of CDI

Ranged from systematic reviews
with meta-analysis to small case
cohort quasi-experimental
studies.

-Exclusion criteria:
none

- No major differences in
side effects from probiotic
intervention. One study
reported significantly less
adverse events in probiotic
group than placebo/control
versus placebo/control
group.

-Cost effective/ substantial
cost savings to institutions

Note. CDI = Clostridium difficile infection
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